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Abstract 
Many steps go into developing a clinical viral gene therapy. The course starts 
with appropriate disease selection and moves through the many hurdles of in-
vitro testing, animal model validation and proof-of-concept studies, all the way 
through pre-clinical large animal studies. In this thesis, I propose to outline the 
process of developing a translation pathway for a gene therapy using 
recombinant adeno-associated virus (rAAV). I will expand on this outline using 
data that I have generated during the course of my Ph.D. that ranges from animal 
model validation all the way through pre-clinical vector stability studies. Two 
disease models will be discussed throughout this thesis, Cockayne Syndrome 
(CS) and Alpha-1 Antitrypsin Deficiency (AATD). Cockayne Syndrome is a rare 
autosomal recessive genetic disorder involving mutations in either the CSA or 
CSB gene, leading to defects in DNA repair. Clinically this presents as 
progressive degeneration of the central nervous system, retina, cardiovascular 
system, and cochlea, which leads to mental retardation, post-natal growth 
defects, ocular abnormalities, and shortened life expectancy. Alpha-1 antitrypsin 
is a serine protease inhibitor largely produced in the liver that mainly functions to 
inhibit neutrophil elastase within the lung. AATD leads to an increased risk of 
emphysema, with shortened life expectancy, and also results in accumulations of 
mutant AAT polymers in the liver, sometimes leading to liver failure. Using these 
two disease models I will outline the upstream and downstream pre-clinical work 
as well as the transition to clinical trials of a rAAV based gene therapy. 
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CHAPTER I 
Overall Introduction 
 
In my thesis I will outline the steps for developing a human clinical gene therapy 
from the start of molecular target identification all the way through optimizing 
clinical delivery and expression in patients. I will use two different disease 
models, AATD and CS, and original data I have generated, as well as historic 
published data to illustrate this process. 
Designing a gene therapy is relatively straight-forward on paper, indentify a 
disease that requires gene replacement and substitute the missing gene to 
correct the deficiency. However, in order to take a gene therapy from disease to 
cure many potential pitfalls must be overcome along the way. The factors 
necessary for a successful gene therapy include selection of an appropriate gene 
target, an appropriate target organ, an appropriate delivery modality (I will focus 
on Adeno-associated Virus (AAV)), a characterized in-vitro or in-vivo model to 
test the therapy, an appropriate gene product, a therapeutic window for gene 
product levels, and appropriate end-points for clinical efficacy. The pipeline that a 
therapeutic approach must travel is illustrated below. 
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Molecular Mechanism Disease Target
Candidate Product
Proof-of-concept Studies
Pharm/Tox Studies
Phase I (in Disease)
Phase II/III Studies
Post-licensure 
The Translational Pipeline
 
 
The initial step involves selection of a disease that has an appropriate gene 
target. This ideally means that you have a disease where the molecular 
mechanism and disease target underlying the disease process is known. A 
monogenetic disease is ideal, allowing the researcher to target their gene 
therapy approach to a single target. For example, I will discuss the development 
of a gene therapy for Alpha-1 Antitrypsin Deficiency (AATD) and Cockayne 
Syndrome (CS). In both diseases each patient in affected by a mutation in a 
single gene. This means that only one gene product needs to be replaced. The 
second consideration in terms of molecular mechanism/disease target is the 
array of organ systems involved that require correction within the diseased 
individual. If the disease affects an organ system that is difficult to treat with gene 
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therapy, for example skin, that makes it a less ideal target unless new 
technologies are developed to target that organ system. Some diseases are also 
difficult because they may affect more than one organ system that may not be 
targeted simultaneously. For AATD, the organs affected are the lung and the 
liver, but because the AAT protein is secreted into the blood stream following 
production it makes gene therapy targeting simpler because any peripheral organ 
without cell turn-over could technically be used as a biofactory for protein 
production. I will discuss the evolution of AAT gene therapy and target organ 
selection further in Chapter III but the factors that make it an ideal AAV gene 
therapy candidate are outline in Table 1.1. 
 
Advantages of AAT deficiency as a Target for Gene Therapy 
Single gene disorder 
Short length of coding sequence relative to AAV packaging size 
Secreted protein allowing for multiple choices for target cells  
Wide therapeutic window  
Well-established, readily assayed endpoint for clinical trials 
 
Table 1.1. Potential advantages of AAT deficiency as a target for gene therapy 
 
An important consideration when planning an AAV based gene therapy is 
packaging capacity of the vector. This refers to the size of the therapeutic gene 
that will “fit” into the viral capsid. I will discuss this issue further in Chapter II. 
Briefly, in order to have the AAT gene fit into an AAV vector only the coding 
sequence for the gene was used. 
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In order to test the gene therapy product once the molecular mechanism and 
gene target have been discovered an appropriate in-vitro and in-vivo model of 
disease must be available. In the case of AATD and CS we are fortunate to have 
mouse models available that recapitulate at least some aspects of the human 
disease state, allowing in-vivo gene therapy testing in a mammalian model. I will 
discuss the mouse models for each disease further in Chapters II and III and how 
they can be of use in testing potential gene therapies for each disease. 
Once proof-of-concept has been demonstrated an expectation of efficacy, ideally 
in an in-vivo model, then a larger pharmacology/toxicology (pharm/tox) study 
must be performed. This usually includes some component in a larger animal 
model such as a non-human primate or canid. I will discuss the details of the 
pharm/tox and initial phase clinical studies for AATD as an illustration of this 
process in Chapter III.  
Once initial clinical studies have been performed additional obstacles in terms of 
safety and efficacy may need to be overcome. In the case of clinical AATD the 
major hurdle is obtaining serum levels of AAT that are within what is believed to 
be the therapeutic window. In Chapter VI I will present original data that I 
generated in non-human primates to test limb infusion as a method of delivering 
the AAT vector to muscle in order to improve serum levels of the therapeutic 
protein.  
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As a component of pre-clinical work the stability of the AAV vector to be 
administered must be demonstrated. This often involves showing no loss of 
infectivity/efficacy during handling, storage, and delivery. I will present, in 
Chapter VII, original published data demonstrating the stability of AAV in a 
multitude of circumstances. 
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CHAPTER II 
 
Cockayne Syndrome 
 
Introduction 
 
As an introduction to the selection of molecular and disease targets for rAAV 
gene therapy I will discuss my work on Cockayne Syndrome (CS). I will describe 
the pathophysiology of this disease as well as what makes it a candidate for 
rAAV gene therapy. I will outline how I have begun validating existing mouse 
models so that we can employ them in gene therapy vector testing.  
 
Cockayne Syndrome Pathophysiology 
Cockayne Syndrome (CS) is a rare autosomal recessive genetic disorder 
affecting 2 in 1,000,000 births in the United States and Europe. It was originally 
described in 1933 by Edward Alfred Cockayne as a hereditary disease of the 
skin. The majority of CS cases involve mutations in either the CSA (ERCC8 
gene) (~25%) or CSB (ERCC6 gene)(~75%) gene, leading to defects in 
transcription-coupled nucleotide excision DNA repair and RNA polymerase II 
mediated transcription 1-4. Clinically this presents as progressive degeneration of 
the central nervous system, retina, cardiovascular system, and cochlea, which 
leads to mental retardation, post-natal growth defects (cachectic dwarfism), 
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pigmented retinopathy, cataracts, dermal UV sensitivity, organ dysfunction and 
shortened life expectancy 5-7. The cachectic dwarfism often presents in the first 
years of life, although patients who are mildly affected may not be diagnosed 
until adulthood. Two main clinical types have been described, Type I is the 
classic CS disease, with manifestations within the first few years of life, and Type 
II is the more severe form that can manifest prenatally 8. There is no clear 
genotype/phenotype correlation in CS patients, either in terms of 
complementation group or type of mutation present within the CSA or CSB gene 
9. This means that the phenotype a patient will present with cannot be predicted 
by their genetic mutation alone. This is further complicated by the small number 
of cases available for characterization. CSA and CSB are both known to be 
involved in transcription-coupled nucleotide excision repair; however this is not 
believed to be the only function these proteins play within the cell. This 
speculation is based on the fact that Xeroderma Pigmentosum patients, 
completely lacking both global and transcription-coupled nucleotide excision 
repair, exhibit the UV sensitivity seen in CS but not the neurologic deficits 
associated with CS 10,11. CSA is a member of the WD repeat super family (a 
protein with 4 or more copies of an approximately 31 amino-acid tryptophan-
aspartate repeat), with 7 WD repeat regions 12,13. WD repeat proteins have 
diverse functions, but are often associated with stimulating the formation of multi-
protein complexes 14. While the complete function of CSA is not known, CSA is 
known to be part of a larger protein complex with ubiquitin ligase activity thought 
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to regulate ubiquitination of both RNA PolII and CSB. This ubiquitination is 
thought to play a role in the removal of the stalled RNAP II complex, and 
eventually CSB, from DNA lesions 15,16. Like CSA, the function of the CSB 
protein within the cell remains to be fully elucidated. CSB is a member of the 
SWI2/SNF2 ATPase family, known to be involved in transcription, DNA repair 
and chromatin maintenance and remodeling. CSB deficient cells have been 
shown to have a 50% reduction in transcription compared to wild-type cells 4. 
CSB is also believed to play a role in preventing spontaneous oxidative 
mutations in the genome, therefore excessive oxidative products accumulate 
within CSB deficient cells, and may lead to the neurotoxicity seen in CS patients 
13. 
The average life expectancy for CS patients is 12.5 years with some patients 
living into their teens and twenties. At this time, no therapy exists for patients with 
CS and the disease must be managed symptomatically. 
 
Cockayne Syndrome Mouse Models 
Three mouse models of CS have been previously characterized. Mice with 
homozygous mutations of either CSA and CSB alone do not manifest the 
neurologic phenotype seen in CS human patients.  However, as with other 
knockout mouse models, clinically relevant phenotypes may be elicited when the 
animals are challenged with insults that exert stress on the pathway in question, 
in this case DNA repair.  Consistent with this, CSA and CSB mutant mice display 
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signs of retinal degeneration with age and or with exposure to ionizing radiation 
11,17,18. Ionizing radiation leads to increased photoreceptor cell apoptosis. A third 
mouse model has mutations in both the CSB and Xeroderma pigmentosum A 
(XPA) genes. XPA is another nucleotide excision repair protein involved in both 
transcription coupled and global genome repair. XPA mice exhibit a neurologic 
phenotype similar to CSB mice however, CSB/XPA double mutant mice possess 
marked neurologic deficits and post-natal growth failure and don’t survive past 
weaning, similar to severely affected human CS patients 19. Histologically the 
mice show cerebellar morphologic abnormalities accompanied by increased 
apoptosis 19. More recently a defect in energy metabolism has been confirmed in 
CSB mutant mice, a potential contributor to the chronic cachexia seen in patients 
20. These three mouse models will theoretically allow testing of a gene therapy 
approach to treatment of the retinal, metabolic and central nervous system 
dysfunctions that are so devastating to the human patients. It should also be 
noted that the previously published papers examining the retinal phenotype is CS 
mice used CSA and CSB mutant mice on a Balb/C background. Currently the 
only mice I could obtain were on a C57Bl6 background. In the work outlined 
below I have undertaken to confirm the presence of the retinal phenotype in the 
CSA and CSB deficient mouse models on either a C57Bl6 or Balb/C genetic 
background. I also sought to confirm the previously described metabolic 
phenotype in the CSB mutant mice and investigate whether this phenotype is 
present in CSA mutant mice.  
10 
 
 
 
Cockayne Syndrome Adeno-Associated Virus Gene Therapy 
AAV Gene therapy is a potential therapeutic option for CS because of its 
particular suitability to treat monogenetic disorders, such as CS. Adeno-
associated virus (AAV) provides an optimal tool-kit for CS gene therapy. 
Recombinant AAV was first used in human clinical trials by the Flotte lab in 1995, 
since that time multiple clinical trials for several human disorders have been 
conducted, with AAV demonstrating both safety and the ability for long-term 
expression 21,22. AAV is a small (20nm) replication deficient single stranded DNA 
virus of the genus Dependovirus in the Parvovirus family. Well over 100 wild-type 
AAV capsid variants have been identified to date along with many laboratory 
engineered capsids. Tissue/cellular infectivity has been specificity attributed to 
the AAV capsid 23,24. For rAAV the entire AAV genome, with the exception of the 
noncoding inverted terminal repeats, is replaced with the therapeutic gene of 
interest along with a promoter and polyadenylation signal. A major clinical 
limitation of rAAV is its small packaging capacity of ~5kb. One way to address 
this is to only select gene targets that fit within the packaging of the vector. In the 
case of CSA and CSB, CSA is well within the packaging capacity, however CSB 
requires a shortened promoter to be used in order to be small enough to package 
well within an AAV vector (Figure 2.2). Below I will outline the vector constructs 
that I have cloned and tested as well as disease model characterization as 
described above. 
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Methods 
Vector Design 
The vectors were designed to encode the mouse CSA or CSB proteins according 
to the NCBI database. The entire gene sequence was used in both cases. For 
the CSA gene, due to its small size, a full-length chicken beta actin promoter with 
a cytomegalovirus enhancer was utilized (Figure 2.1A). This is the same 
promoter that has been previously used and published in association with the 
AATD clinical vector 25-27. In order to potentially increase expression, a double 
stranded CSA vector was also cloned with a mutant inverted terminal repeat. In 
order to keep this vector under 5kb, a shortened chicken beta actin promoter was 
utilized (Figure 2.1B). For the CSB gene, because of its large size, this same 
shortened chicken beta actin promoter was utilized to keep the total construct 
under 5kb (Figure 2.2).  
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Figure 2.1 CSA rAAV Constructs. A. CSA constructs with full-length chicken beta-actin 
promoter with cytomegalovirus enhancer. B. Self-complimentary CSA constructs with 
shortened chicken beta-actin promoter and mutant ITR. ITR = AAV inverted terminal 
repeat. CMV-CB = Chicken beta-actin promoter with cytomegalovirus enhancer. nGFP = 
Nuclear GFP reporter gene. PA = SV40 polyadenylation sequence. C-myc = reporter 
sequence tag. CB = Truncated chicken beta-actin promoter.  
 
 
 
Figure 2.2 CSB rAAV Constructs. CSB constructs with shortened chicken beta-actin 
promoter ITR = AAV inverted terminal repeat. nGFP = Nuclear GFP reporter gene. PA = 
SV40 polyadenylation sequence. C-myc = reporter sequence tag. CB = Truncated 
chicken beta-actin promoter.  
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CBS mRNA Expression in CSB Mutant Mice 
Adult (12 week old) CSB mutant mice were given 1x1012 vector genomes of 
AAV9 CBshortCSB by intravenous injection, while a control mouse was injected 
with phosphate buffered saline intravenously. The mice were sacrificed 3 weeks 
later and the liver was collected and snap frozen for RNA extraction. RNA 
extraction was carried out using the Qiagen RNeasy kit with gDNA eliminator 
column according to the manufacturer’s instructions. cDNA was generated using 
the High-Capacity cDNA RT kit (Applied Biosystems). qRT-PCR was performed 
using primers designed to target the CSB gene and compared to HPRT as a 
housekeeping gene. Data was analyzed using StepOne Software (Applied 
Biosystems, Carlsbad, California 92008). 
Electroretinography (ERG) 
ERG was performed as described in Ma et al 2015 using the Espion3 console in 
conjunction with the ColorDome (Diagnosys LLC, Lowell, MA, USA)28. In brief, 
mice were dark-adapted for a minimum of 1 hour to overnight for scotopic ERGs 
and anesthetized by an intraperitoneal injection of ketamine/xylazine (100 mg/kg 
and 10 mg/kg). Phenylephrine (2.5%) and Tropicamide (1%) was applied to the 
cornea at least 8-10 minutes prior to testing in order to fully dilate the pupils. 
Animals were kept on a warming plate or in a heating cage from anesthesia 
through the entire ERG procedure to maintain the body temperature as close as 
possible to 37 °C. The dark-adapted ERG protocol consisted of five steps with 
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increasing stimulus strengths from 0.009 to 100 cd s/m2, with a mixed white light 
(white 6500 K) produced by a Ganzfeld stimulator. All flashes were presented in 
a dark environment with constant interstimulus intervals of 5 seconds for dim 
flashes and up to 30 seconds for bright flashes to maintain the established dark 
adaptation. Flash frequency was 0.07 Hz for bright flashes and up to 0.5 Hz for 
dim flashes. Photopic ERGs were performed after scotopic testing on the same 
anesthesia setting. Photopic ERGs were recorded after light adaptation with a 
background illumination of 34 cd/m2 (white 6500 K) for a minimum of 8 minutes. 
Each recording consisted of 10 single flash of 10 cd s/m2. Five trials were 
averaged for single-flash responses. ERGs were performed with a gold wire 
electrode.  
Retinal Degeneration with Age in CSA and CSB Mice 
CSA and CSB homozygous and heterozygous mutants along with age-matched 
C57Bl6 controls were followed from 6-8 weeks of age until 10-15 months of age 
with ERGs performed every 6 weeks initially then every 8-12 weeks. Due to 
death loses during the ERG procedure (secondary to anesthesia) we were not 
able to regularly sacrifice any mice as planned to follow the histology 
concurrently.  
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High Intensity Light Exposure 
CSA mutant mice and wild-type litter-mates on a BALB/C background (F2 
backcross generation) were exposed to high intensity (5000 lux) light for 20 
minutes. ERGs were performed prior to light exposure and again two weeks after 
exposure. Animals were then sacrificed and retinas collected for cryosection. 
Apoptosis was detected using the TACS 2 Tdt-DAB In Situ Apoptosis Detection 
Kit (Trevigen, 4810-30-K) (n = 1-3 mice per group). 
 
Calorie Restriction 
Calorie restriction was performed as described previously in adult CSA and CSB 
mutant mice on a C57Bl6 background with age-matched C57Bl6 mice serving as 
controls 20. As described the mice were initially calorie restricted by 40% (as 
calculated based on average amount eaten over three days when singly 
housed). However, both the CSA and CSB calorie restricted mice began showing 
evidence of hypoglycemia with this level of restriction, so their intake was 
increased by 10% to 30% of initial food intake. They were calorie restricted for 9 
weeks with body weight recorded weekly. Body weights and blood glucose were 
analyzed at the end of the study prior to sacrifice. A total n of 3-6 mice were 
present per group at the end of the study. 
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Statistics 
Data was analyzed using commercial software (GraphPad Prism 6). Multiple t-
tests were employed not assuming equally distributed SD and applying the Holm-
Sidak method to correct for multiple comparisons. 
 
Results 
 
CSB Vector Tissue Expression 
I was able to demonstrate liver expression of CSB mRNA in mice injected with 
AAV9 CBshort-CSB intravenously (Figure 2.3). Only mice injected with the vector 
encoding for CSB had detectable CSB mRNA compared to a PBS injected 
animal. No contaminating genomic DNA was detected in our –RT control 
samples. 
 
Retinal Degeneration with Age in CSA and CSB Mice 
Both CSA and CSB mutant mice on a C57Bl6 background show slow loss of 
photoreceptors over time based on the slow decline of B-wave amplitude by ERG 
(Figure 2.4). However, the decline is slower than and not as dramatic as 
previously published by other groups. By 10-15 months both homozygous and 
17 
 
 
heterozygous CSA and CSB mutant mice show a dramatic decrease from 
baseline ERG readings at 4-6 weeks of age (Figure 2.4).  
 
 
Figure 2.3 RT qPCR for CSB mRNA following AAV9 CSshort-CSB vector delivery. 
CSB mRNA detectable in the liver of all three animals to which vector was delivered 
intravenously compared to a PBS injected mouse. Each bar represents a single CSB 
mutant animal. 
 
High Intensity Light Exposure 
When CSA and CSB mice on the C57Bl6 background were exposed to high 
intensity light, we did not see a change in scotopic B-wave amplitude compared 
to control mice even after 17 hours of high-intensity (5000lux) light exposure 
(data not shown). This led us to breed and investigate CS mice on a Balb/C 
background. Following high intensity light exposure CSA mutant and control 
littermates on the Balb/C background demonstrated a minimal decrease in B-
wave amplitude (Figure 2.5A). When the groups are compared to their baseline 
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B-wave values only the CSA-/- group exposed to light had a decrease to 72.6% 
of baseline amplitude (Figure 2.5B). When the number of apoptotic photoreceptor 
cells in the outer nuclear layer of the retina were examined there was a 
significant difference between the CSA-/- and CSA+/+ animals (P=0.010) with 
CSA negative animals having a significant increase in the number of apoptotic 
photoreceptors (Figure 2.6). 
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Figure 2.4 Electroretinography of CSA and CSB Mutant Mice on a C57Bl6 
Background with Age. A. Scotopic 1 B-wave amplitude in aging CSB mutant and 
control C57Bl6 mice. B. Scotopic 1 B-wave amplitude in aging CSA mutant and control 
C57Bl6 mice. C. The percentage of baseline B-wave amplitude at oldest age groups (10-
15 months). Graphs represent the mean +/- SD. 
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Calorie Restriction 
Following calorie restriction for 9 weeks we found that there was a significant 
decrease in body weight in the CSA and CSB mutant mice compared to mice of 
the same genotype that were not calorie restricted, CSA (P=0.008) and CSB 
(P=0.017)(Figure 2.7). There was also a significant decrease in blood glucose in 
the CSA mutant mice following calorie restriction compared to unrestricted age-
matched controls (P=0.017). Both CSA and CSB calorie restricted mice had 
significantly lower blood glucose levels compared to calorie restricted C57Bl6 
control mice, CSA (P=0.001) and CSB (P=0.025)(Figure 2.8). 
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Figure 2.5 Electroretinography of CSA Mutant Mice Following High-Intensity Light 
Exposure. CSA mice on a Balb/C genetic background were exposed to high intensity 
light (5000lux for 20 minutes). A. Average B-wave values from scotopic level 5 (highest 
intensity light) ERG. B. Percentage of baseline scotopic level 5 B-wave amplitude. n = 1-
3 per group. Graphs represent the mean +/- SEM. 
 
20 
 
 
Summary 
I have been able to design, clone and package the vectors necessary to undergo 
gene therapy in mouse models of CS. I have tested the CSB vector and shown 
mRNA expression within the liver. Protein expression has been more difficult to 
demonstrate for either CSA or CSB in mouse tissue. This is likely due to the fact 
that the CSA and CSB antibodies that are available commercially are human 
antibodies and/or have not been validated for either Western blot or 
immunohistochemistry in tissues. I have also tested several c-myc antibodies 
and have not been able to obtain a suitable signal on either tissue 
immunostaining or Western blot. This is a difficulty that we have had with the c-
myc tag in other vectors within the lab, despite the fact that these same 
antibodies function well in ELISA assays to detect those same gene products.  
This leads me to believe that this is not a problem with my construct.  
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Figure 2.6 Average Number of Apoptotic Photoreceptors in the Outer Nuclear 
Layer of the Retina. The average number of apototic cells were averaged over 8-11 
sections in 1-2 mice per group. CSA -/- mice had significantly more apoptotic cells 
compared to CSA +/+ mice (P=0.010). Graph represents mean +/- SEM. 
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Figure 2.7 Body weights following calorie restriction for 9 weeks. CSA and CSB 
mutant mice on a C57Bl6 background were calorie restricted for 9 weeks and the body 
weight at the end of that time was compared to control C57Bl6 mice as well and ad-
libidum fed (no restriction) CSA and CSB deficient mice. There was a significant 
difference in body weight between unrestricted CSA (P=0.008) and CSB (P=0.017) 
mutant mice compared to their no restriction controls. There was no significant 
difference in weight between the restricted and unrestricted C57Bl6 control mice. N = 3-6 
mice per group. Graph represents mean +/- SEM. 
 
Based on my evaluation of the retinal degeneration seen over time in the CSA 
and CSB mutant mice on the C57Bl6 background we have concluded that these 
mice do not show the same level and degree of retinal degeneration as that 
previously reported on the Balb/C background. This is consistent with what other 
groups have seen in C57Bl6 mice and seems to be a strain-specific difference in 
photoreceptor sensitivity 29. This led us to begin backcrossing our mice onto the 
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Balb/C genetic background in order to have a CS model that better recapitulates 
the retinal phenotypes seen in patients. Previous reports have demonstrated that 
sensitivity to light returns to Balb/C mice on the C57Bl6 background by the F2 
generation 29. Based on this data we looked at the return to sensitivity to high 
intensity light in CSA-/- Balb/C F2 mice and their wild-type littermates and found 
that only the CSA-/- mice demonstrated a decrease in scotopic B-wave amplitude 
and demonstrated an increase in apoptotic photoreceptors. I hope that this will 
provide us with a potential phenotype to which we can apply a gene therapy 
approach to correction. 
Based on work performed by another group demonstrating a metabolic 
phenotype in CSB mice when they are calorie restricted and then fasted for a 
short period we wanted to recapitulate that phenotype within our CSB colony as 
well as investigate whether the same phenotype could be observed in the CSA 
mutant mice 20.  We found that both CSA and CSB mutant mice had a drop in 
body weight following calorie restriction when compared to unrestricted controls. 
Calorie restriction in control C57Bl6 mice (the genetic background of the CSA 
and CSB mice used in this study) did not result in the same drop in body weight. 
We also observed a significant drop in baseline blood glucose in calorie 
restricted mice compared to wild-type controls. Interestingly we were not able to  
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Figure 2.8 Blood Glucose following calorie restriction for 9 weeks. CSA and CSB 
mutant mice on a C57Bl6 background were calorie restricted for 9 weeks and the blood 
glucose at the end of that time was compared to control C57Bl6 mice as well and ad-
libidum fed (no restriction) CSA and CSB deficient mice. There was a significant 
difference in blood glucose in CSA mutant mice following calorie restriction compared to 
unrestricted mice (P=0.017) Both CSA and CSB calorie restricted mice had significantly 
lower blood glucose levels compared to calorie restricted C57Bl6 control mice (CSA 
(P=0.001) and CSB (P=0.025)). N = 3-6 mice per group. Graph represents mean +/- 
SEM. 
 
restrict the calories of our CSA and CSB mutant mice to the same degree as 
reported in the literature because it resulted in signs of severe hypoglycemia and 
death in several mice. We did not see any hypoglycemia or death in the calorie 
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restricted control mice. It may be that we calculated the calorie restriction of our 
mice differently than what was reported in the literature or it may be that because 
we started the calorie restriction in somewhat younger mice than previously used 
that they had increased caloric demands due the growth that led to the observed 
clinical signs. In any case, this is a potentially valuable phenotype that could be 
used to test the efficacy of a liver directed gene therapy. One of the major clinical 
morbidities in CS patients is their inability to maintain adequate body condition 
and growth potential despite intensive dietary management. Correction of this 
cachexia phenotype could dramatically improve quality of life for these patients.  
Overall, I have shown that CS has strong potential as a target for rAAV directed 
gene therapy based on appropriate molecular targets and in-vivo models with 
multiple relevant phenotypes with which efficacy can be tested (Table 1.1). 
Because of the small number of CS patients that have been available to 
genotypic and phenotypic examination, the exploration of new phenotypes within 
the CS mouse models could shed valuable new light on this devastating rare 
disease.  The lack of adequate assays for protein expression should not prevent 
translation in this model, if vector-mediated mRNA expression is consistently 
correlated with correction of the CS-specific phenotype. 
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Genotype Challenge Phenotype Comments 
CSA-/-, CSA-/+ 
CSB-/-, CSB-/+ 
 
Aging  Decreased 
Rod Activity 
C57Bl6 
Background 
CSA-/-  High-intensity 
light exposure 
Decrease Rod 
Activity 
Photoreceptor 
Apoptosis 
Balb/C 
Background 
CSA-/-, CSB-/- Calorie 
Restriction 
Hypoglycemia 
Weight Loss 
C57Bl6 
Background 
 
Table 2.1 Phenotypes elicited with various Cockayne syndrome knockout mice. 
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CHAPTER III 
 
Progress in Recombinant Adeno-Associated Virus Vectors for Gene Therapy of 
Alpha-1 Antitrypsin Deficiency  
 
Introduction 
Here I will discuss the methodology that went into designing the pre-clinical and 
clinical investigations for the adeno-associated virus (AAV) clinical gene therapy 
vector for alpha-1 antitrypsin (AAT) deficiency, how the therapy has evolved as a 
result of this work, and the potential course for future research and clinical trials. 
This overview was originally published in Human Gene Therapy Methods and is 
intended to provide insight to investigators who are working on translating a 
therapeutic plan for their disease of interest.  
Alpha-1 antitrypsin, also termed SERPINA1, is a serine protease inhibitor largely 
produced in the liver. AAT is secreted from hepatocytes and carries out the 
majority of its function to inhibit neutrophil elastase and other neutrophil-derived 
proteases and defensins within the lung. Mutations in AAT that decrease serum 
levels lead to an increased risk of emphysema, with shortened life expectancy. 
Life expectancy is further decreased in smokers and ex-smokers.30 Mutations in 
AAT can also result in sporadic liver disease as the result of accumulations of 
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mutant AAT polymers, specifically the PiZ mutant protein (glu342lys, E342K), 
within the hepatic endoplasmic reticulum.31-34 
AAT deficiency is perfectly suited for a gene therapy approach to treatment for 
several reasons (See Table 1.1). It is a monogenetic disorder; meaning that the 
gene therapy vector will need only to deliver the single AAT gene itself in order to 
correct the phenotype. Another positive feature as a target for gene therapy is 
that there is a wide therapeutic range for serum AAT levels, eliminating the need 
for tight transcriptional control. Previous work has shown that serum levels of 
AAT of 11uM/L (571ug/ml) are necessary to prevent lung disease and protein 
replacement studies have established that levels greater than 80mg/ml have no 
adverse clinical effect.  Protein replacement in AAT deficient individuals has also 
established that human AAT can be delivered without immune responses. In 
terms of gene therapy vector production, AAT has the advantage of a coding 
sequence small enough to be easily packaged within an adeno-associated virus. 
Gene therapy delivery options are widened because AAT is a secreted protein, 
allowing for production of AAT from sites other than the lung or liver, such as the 
muscle, while still reaching the intended target, the lung. Finally, the precisely 
defined therapeutic threshold of 11uM/L on a simple blood test provides an ideal 
endpoint for clinical trials and eventual licensure of a rAAV-AAT gene therapy 
product. 
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While other gene delivery methods (recombinant Adenoviral vectors, cationic 
liposome vector delivery, retroviral vectors and naked DNA injections) were 
initially tried, subsequent gene therapy attempts have focused on correction of 
the lung phenotype via an adeno-associated virus (AAV) vector encoding wild-
type human AAT delivered to skeletal muscle.35-41  
 
Pre-clinical Development of rAAV2-AAT Vectors 
Selection of route and construct design 
 While hepatic delivery of a therapeutic AAT encoding vector would be the 
most physiologic source for expression, there has long been a concern that 
driving increased AAT expression in hepatocytes already burdened with 
subclinical disease (as might be found in patients with Z-AAT accumulation or 
latent virus infection) could precipitate hepatic injury or failure.42 Early work 
demonstrated that sustained AAT expression and secretion could be obtained 
from skeletal myofibers alleviating the concern of precipitating liver disease.43 
Several promoters were tested to optimize expression of AAT.  Ultimately a 
hybrid cytomegalovirus (CMV) enhancer with a chicken beta-actin promoter and 
a hybrid rabbit beta-globin intron was found to have the most robust AAT 
expression from liver and was subsequently confirmed to be effective in 
intramuscular baboon studies.25,26 
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Mouse and primate studies 
Initial work in the lab demonstrated that human AAT could be expressed long-
term from C57BL/6 mice following intramuscular injection with a rAAV2-AAT 
vector with minimal immune response.43 This allowed for toxicology and 
biodistribution studies to be performed in C57BL/6 mice using the planned 
clinical human gene therapy DNA construct.44 Toxicology/biodistribution was 
performed following intramuscular and intravenous (to mimic inadvertent 
intravascular delivery in a patient) delivery. Widespread distribution was less 
following intramuscular injection and no vector DNA was detected in the gonads 
of the mice. Similar results were obtained when vector was delivered to New 
Zealand white rabbits, including a lack (or very low copy number) of vector 
genomes present in the gonads.44 
A safety study performed in a baboon model showed no significant adverse 
events.26 However, when the baboons were administered vector encoding the 
human AAT (hAAT) gene, circulating anti-hAAT antibodies were generated. This 
result is similar to that seen previously in Balb-C mice. No anti-AAT antibodies 
were generated when the baboons were administered a vector encoding the 
baboon AAT gene. Mild muscle inflammation around the injection site was seen 
in both vector and non-vector injected animals. Serum creatine kinase levels, a 
marker of myofiber injury, were elevated in only four samples, with 3 of those 
samples collected either before vector delivery or in a saline control animal. This 
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indicates that the creatine kinase level increases were likely not due to the gene 
therapy. 
Germline transmission was also assessed by assaying for vector DNA in gonadal 
tissue 4 months after vector delivery via quantitative real-time PCR. At that time-
point, vector DNA copy numbers were at or below the limit of detection in the 
gonads examined (< 40-400 vg copies/10,000 cell genomes). This study was one 
of the final steps in the pre-clinical vector development and safety testing prior to 
proceeding to clinical trials. 
 
Phase 1 Clinical Trial: AAV2 (Published 2006) 
The first human clinical trial of an AAV encoding hAAT protein was published in 
2006.27  Protein replacement therapy was discontinued 28 days prior to dosing in 
patients receiving protein replacement. The dose of recombinant AAV2 encoding 
hAAT was given at a dose range of 2.1 x 1012 to 6.9 x 1013 vg delivered 
intramuscularly into the upper arm (deltoid muscle) of the non-dominant arm. The 
construct was driven by a chicken beta-actin promoter with a CMV enhancer.  A 
CT scan of the upper arm was performed prior to injection to confirm normal 
muscle morphology. Doppler ultrasonography during the injection confirmed that 
major arteries and veins were avoided. No serious adverse events were recorded 
in this study, including a lack of muscle toxicity as evidenced by normal physical 
examination and serum creatine kinase levels (a marker of muscle damage). No 
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muscle biopsies were performed in this clinical trial. Pre-existing anti-AAV 
antibodies were recorded in all patients prior to dosing, with antibody levels 
increasing following dosing with the clinical vector. Anti-AAT antibodies were low 
in patients prior to dosing with no increase measured following vector 
administration. Residual M-AAT levels were measured in patients receiving 
protein replacement therapy, due to an apparently inadequate washout period 
prior to vector dosing. These residual levels likely made detection of vector 
derived M-AAT impossible as one patient that was not on protein replacement 
therapy prior to dosing had vector derived levels within the range of the residual 
amounts seen in the replacement therapy patients. Based on the prior mouse 
studies, one might have predicted that a dosage of 1x1012 vg/kg would be 
required to achieve detectible levels in patient serum. Therefore, the fact that 
serum levels were low or undetectable in this trial was not surprising.  At the 
time, it was anticipated that rAAV2 might have expressed higher levels in 
humans on a vg/kg basis than it had in mice, but this was not observed with 
rAAV2-AAT. 
 
Alternatives to AAV2 and Preclinical Toxicology/Biodistribution of AAV1 
(Published 2006, 2007) 
In parallel with the AAV2 clinical trial discussed above, investigation began 
looking at whether there were AAV serotypes that would result in more efficient 
32 
 
 
muscle AAT expression. Previous work in other labs had shown an advantage of 
other rAAV serotypes over AAV2 for Factor IX expression.45,46 In 2006 Lu et al. 
determined that of rAAV1-5, rAAV1 had the most efficient murine muscle 
transduction, resulting in AAT serum levels 100-fold higher than with rAAV2 
delivery.47 They also determined that the resultant AAT was able to interact with 
neutrophil elastase and had the same level of elastase inhibition as human liver 
derived AAT.47  
With the sub-therapeutic serum AAT levels in the AAV2 clinical trial discussed 
above and this data showing a marked advantage of AAV1 the decision was 
made to move to AAV1 for subsequent clinical trials. In order to progress to the 
clinics a toxicity/biodistribution study was performed in 170 C57Bl/6 mice and 26 
New Zealand White rabbits.48 The DNA construct was identical to that used in the 
rAAV2 study. Mouse toxicology (3 dose groups) included histology on all major 
organs as well as isolation of genomic DNA from these organs, as well as blood, 
to assay for vector genomes following intramuscular injections. The murine 
biodistribution study (3 dose groups) was performed following either 
intramuscular or intravenous delivery (to mimic an inadvertent intravascular 
delivery in a patient). Vector genome analysis was performed in all major organs, 
with particular importance placed on vector genomes in the gonadal DNA. An 
identical study, with the addition of the GFP group (GFP within an identical 
backbone) and analysis of serial semen collection to assess the possibility of 
germline transmission was performed in rabbits. At higher doses (1.2 x 1013 
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vg/kg) muscle inflammation at the injection site, anti-AAT antibody responses 
and the presence of vector DNA in both the blood as well as peripheral organs 
(including the gonads) could be seen in mice. At a dose of 3 x 1012 vg/kg vector 
DNA was also detected in the semen and gonads of rabbits. In both mouse and 
rabbits vector copy number was highest at earlier time points with concentration 
decreasing over time. It should be noted that the cell-type within the semen or 
gonads in which the vector DNA was present was not determined; therefore this 
data does not indicate that germline transmission was possible.  
 
Phase 1 Clinical Trial: AAV1 (Published 2009) 
As discussed above, transgene derived hAAT levels in the first clinical trial were 
only above background in 1 of the 12 subjects dosed, a strategy to improve 
expression was sought that involved switching to an AAV1 capsid.27,49 For this 
phase 1 trial, the same hAAT gene cassette used in the first trial was packaged 
in the AAV1 capsid and 9 AAT deficient (<11uM) patients were dosed by 
intramuscular injection. Vector doses were similar to the first trial at 6.9 x 1012, 
2.2 x 1013, and 6.0 x 1013 vector genomes per subject. Mild injection site 
reactions were seen in 7 of 9 subjects following dosing and one subject 
developed an E. coli epidiymitis (deemed unrelated to vector injection). No 
abnormalities in serum chemistry, including creatine kinase levels, or hematology 
were noted. Vector DNA was detected in the blood of 2 of 3 patients in the lower 
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dose cohorts and 3 of 3 patients in highest dose cohort. Vector DNA was 
undetectable in all subjects but 1 by day 14 or 90. Unlike the rabbits, the patient 
semen had no detectable vector DNA. Patients in the highest dose cohort 
maintained subtherapeutic levels for at least 90 days and up to 1 year in the face 
of an effector T cell response to AAV capsid. No immune response was detected 
against hAAT.  
 
Phase 2 Clinical Trial: AAV1 (Interim Results Published 2011, Final Results 
2013) 
Because the phase 1 trial with AAV1 encoding the hAAT showed evidence of 
dose-dependent expression, but at sub-therapeutic levels, phase 2 employed a 
dose-escalation in order to increase transgene expression.50 The previous 2 
clinical trials of AAV encoding hAAT used a plasmid transfection method to 
produce the clinical vector.27,49 However, previous work has shown that the use 
of a recombinant herpes simplex virus (HSV) complementation system can result 
in greater vector yields (and modestly increased infectivity of vector on a per vg 
basis), allowing for dose escalation.51,52 HSV complementation was validated in a 
mouse toxicology study comparing the previously used transfection method and 
found to increase packaging efficiency and expression and carry a similar safety 
profile compared to the transfection method.53 
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The phase 2 clinical trial consisted of three dose cohorts of rAAV1-CB-hAAT at 
6x1011, 1.9x1012, or 6x1012 vg/kg, with 3 patients per cohort. Due to the limits of 
vector concentration without causing viral precipitation it was necessary to deliver 
the highest dose cohort’s vector in 100 intramuscular injections. Significantly, this 
trial demonstrated a linear serum M-AAT (wild-type AAT) dose response 
relationship.25 However, the serum AAT levels were still well below thresholds set 
for a therapeutic effect. Interestingly, despite the presence of CD8 positive T 
lymphocytes being present in the injected muscle at day 90, serum M-AAT levels 
persisted in patients at stable levels for over 1 year without the need for 
immunosuppressive therapy.50,54 Further characterization of the inflammatory 
infiltrate surrounding the myofibers expressing AAT determined that a population 
of regulatory T cells was present that was activated in response to AAV capsid.54 
This regulatory response is likely what allowed the long-term AAT expression in 
the face of the inflammatory infiltration.  
 
Summary 
While the preceding narrative demonstrates that significant advances in 
expression level can be obtained through alterations in vector design (promoter 
choice for example) and serotype selection (rAAV2  rAAV1), there is still a 
need to increase serum AAT levels further in order to obtain therapeutic levels. 
There are many strategies that can be employed either alone or in combination 
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that could increase expression levels of AAT. One way to increase expression is 
to increase the number of myocytes that are transduced by the vector. One way 
that has been shown to effectively target the entire limb is to employ a regional 
limb delivery method, whereby the vector is delivered into the vasculature of a 
limb that has been isolated from the systemic circulation using a tourniquet.55-62 
These methods have long been used in human patients to treat limb neoplasia 
and proof of concept gene therapy delivery studies have been performed in 
patients with muscular dystrophy.56,58,62  There is also evidence that limb infusion 
delivery has a lower level of immune stimulation compared to intramuscular 
delivery, which may increase transgene expression.61 I will discuss this method 
and how we employed it in non-human primates further in Chapters V and VI. 
Other methods to decrease the immune response could be employed, including 
systemic immunosuppression either in response to clinical evidence of 
inflammation (rise in serum creatine kinase, indicating myocyte damage) or 
prophylactically for a short period of time beginning at or prior to vector delivery 
to prevent an immune response from being initiated. Another strategy to 
decrease the immune response might be to select or create a capsid type with 
lower pre-existing immunity or immune profile in humans.63-65 Expression could 
be potentially increased through codon optimization of the AAT gene or through 
the use of self-complimentary AAV vectors.  
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Another approach to therapy for AAT deficiency would be to safely target 
hepatocytes by using RNAi, zinc finger or CRISPR/Cas9 technologies to stop 
expression of mutant PiZ in the liver, allowing safe expression of wild-type M-
AAT from hepatocytes, either providing a “liver-sparing” lung disease gene 
therapy or potentially a mode to treat both liver and lung disease. Our laboratory 
has demonstrated that RNAi technology can be used to decrease PiZ expression 
either alone or in the form of a dual-function vector that allows simultaneous 
knock-down of mutant AAT and expression of wild-type AAT.66,67 Zinc finger 
technology delivered via AAVs has been used to target the liver in a hemophilia 
model.68 Proof of concept studies have also demonstrated that CRISPR/Cas9 
technology can be used to target the liver to treat a genetic disease.69 With all of 
the new technologies available to address AAT gene therapy, the future 
prospects for licensed gene therapy products for this disease seem very bright. 
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CHAPTER IV 
 
Lung Delivery of AAV 
 
Introduction 
While the direction of AAT gene therapy is to deliver to muscle, other organ 
systems, such as lung have been considered. In the following chapter, I will look 
at the pros and cons of lung directed gene therapy and present original data 
looking at intratracheal delivery of an AAT gene therapy vector. 
 
Delivery of AAV to the lung in mice 
The lung was the target of the first human rAAV trial 21. In that trial a rAAV2 
vector was used to deliver the CFTR gene to the lung of cystic fibrosis patients.  
rAAV has been used in multiple human trials subsequently, targeting the lung as 
well as other organ systems. While the safety of rAAV in human trials has been 
established, other challenges to efficient long-term gene transfer were 
encountered 67,70.  
The initial gene therapy trials involving the lung have shown rAAV to be a safe 
vector for human gene therapy, with only transient moderate adverse events 
being reported in any of the clinical trials published thus far. However, efficient 
gene therapy in the lung has encountered other obstacles.  The original cystic 
fibrosis trial used rAAV2 to deliver the CFTR gene, with only low levels of 
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expression seen within the lung. It was discovered that rAAV2 requires heparin 
sulfate proteoglycans (HSP) for efficient cell entry 71.  HSPs are only located on 
the basolateral surface of airway epithelial cells, not the apical surface. This 
necessitates disruption of the tight junctions between airway epithelial cells in 
order to allow the rAAV2 viral vector to gain access to the HSP receptors. 
Subsequently other serotypes have shown improved lung transduction, without 
the necessity for tight junction disruption, due to the presence of apical surface 
receptors. Currently the most promising vectors for lung-targeted gene therapy 
include AAV5, AAV6, AAV9 and AAV6.2. The choice of serotype should be 
based on the cell type that is being targeted (Table 4.1). It should be noted 
however, that Table 4.1 focuses on transduction efficiency in murine models, it 
has been shown that murine and lower primate models may not reflect the 
transduction efficiency in higher primates, specifically chimpanzees and 
humans.72,73 Specifically, AAV5 showed higher efficiency in mouse and lower 
primate models, whereas AAV1 had improved efficiency in human airway 
epithelial cells and chimpanzees airways.72,73 
An additional problem encountered in rAAV mediated gene transfer to the lung is 
the lack of transgene persistence in the dividing epithelial cell population. This is 
due to the fact that, as mentioned above, rAAV is present in transduced cells as 
an extra-chromosomal element.74 This lack of persistence is compounded by the 
fact that repeated dosing of rAAV leads to inefficient transduction, depending on 
serotype, as a result of neutralizing antibodies directed against the AAV capsid.75 
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Transgene expression in the murine lung following a single vector administration 
has been detected up to 217 days after dosing, with a decrease in transgene 
expression occurring between day  49 and 77 and vector genomes between day 
28 and 90.76 
Table 4.1 Airway Serotype Specificity in Mice (Gruntman et al. 2012) 
 
 
 
Neutralizing antibodies directed against AAV capsid are the main immune 
impediment to successful rAAV transduction, although T cell and innate immune 
responses, such as alveolar macrophages and certain pattern recognition 
receptors also pose a potential challenge.70,77 Preexisting immunity to AAV is of 
particular concern when selecting a serotype for experimentation with future 
consideration of translation to human subjects. The prevalence of preexisting 
antibodies in humans is largely serotype dependent, although significant cross-
Serotype Cells Transduced Surface Transduced Transduction Level Receptor Reference 
rAAV2 Alveolar cells 
Smooth Muscle 
Basolateral >>>apical  Heparin 
Sulfate 
Halbert (2001 
and 1998), 
Liberis (2006) 
rAAV5 Conducting airway 
 
Alveolar Cells 
Basolateral>apical Higher than rAAV9 PDGFR, 2-5-
linked sialic 
acid 
Limberis(2006) 
Zabner (2000) 
Pasquale 
(2003) 
Walters (2001) 
rAAV6 
 
 
 
 
 
 
Bronchial 
epithelium 
 
Distal Airway 
epithelium 
 
Alveolar cells 
Apical Higher than rAAV2 
(28-74 fold) 
 
Higher than rAAV2 
(15-34 fold) 
 
Lower than rAAV2 
Sialylated 
glycoproteins 
Halbert (2001) 
rAAV6.2 Alveolar and airway 
cells 
Apical Higher than rAAV6, 
rAAV5, and rAAV9 
 Limberis (2009) 
rAAV9 Alveolar Cells 
>Airway 
Basolateral and apical Higher expression 
on repeat dosing 
versus rAAV5 
Glycans with 
terminal 
galactose 
Limberis(2006) 
Bell (2011) 
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reactivity exists between some serotypes.78 Neutralizing antibodies in humans 
are most prevalent against AAV serotypes 1 and 2, with lower prevalence and 
titers for 5, 8, and 9.78 In cystic fibrosis patients, AAV2 neutralizing antibody titers 
were slightly higher than titers against AAV5 and AAV6 and adults demonstrated 
significantly higher titers than children.79 It is also possible to have an immune 
response directed toward the delivered transgene.77,80 This has further reaching 
implications for patient trials as it could preclude other treatments such as protein 
replacement therapy.77 Neutralizing antibody titers have also been shown to 
increase in patients following rAAV2 vector delivery to the lung, especially 
evident following repeat dosing.81,82 
Physical barriers to efficient vector delivery also exist in the lung, including loss in 
the upper and conducting airways and gastrointestinal tract following intranasal 
delivery.83 Barriers within the lung include the mucociliary clearance system, the 
luminal epithelial glycocalyx, and as mentioned above, tight junction between 
airway epithelial cells.84 There are also disease specific impediments to vector 
lung access, such as the viscous mucus layer that coats the respiratory 
epithelium in cases of cystic fibrosis.85   
All these factors must be taken into account when planning gene transfer 
experiments in the lung. When choosing a reporter or therapeutic rAAV gene 
construct a plan for determining transgene expression efficiency must be 
carefully designed. Some important factors to consider are whether the 
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transgene is an intracellular or secreted protein. Are there diagnostic tests readily 
available to detect the transgene product such as ELISA, immunohistochemistry, 
and Western blot? It has been established that a significant amount of vector 
reaches the liver following respiratory tract delivery.76 If the transgene product is 
secreted, is there a way to determine whether production is occurring due to lung 
transduction or transduction of another organ such as the liver?  
Immunohistochemistry or Western blot of the lung to detect gene product within 
lung cells or detection of gene product within bronchoalveolar lavage fluid can aid 
in proving lung origin gene product. It is also important to determine whether 
gene product expression levels are due to serotype transduction efficiency 
versus gene or promoter efficiency. Determining vector genomes within the lung 
tissue by quantitative real-time PCR can help parse out this difference. For 
example, if vector genomes present are high, but gene product levels are low, 
the low level of gene product could be attributable to multiple factors that affect 
transgene expression, other than poor vector distribution, such as abnormalities 
in viral intracellular trafficking, nuclear targeting, uncoating, and DNA 
processing.86,87   
Based on the knowledge that vector delivery to the lung can result in the 
presence of vector genomes within the liver we wanted to test the efficacy of the 
previously published vector that is capable of both augmenting wild-type AAT as 
well as knocking down PiZ mutant AAT using an artificial miRNA following 
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intratracheal vector delivery. 88 The following data describes the findings of that 
study. 
 
Methods 
Mice 
Mice for experiments involving the C57Bl/6 strain were purchased from Charles 
River Laboratories (Wilmington, MA, USA) and used at 6-8 weeks of age.  The 
PiZ-transgenic mice 66 used in this study were bred in-house at the University of 
Massachusetts Medical School. Mice were housed under specific pathogen-free 
conditions at either the University of Pennsylvania’s Translational Research 
Laboratories or at the University of Massachusetts Medical School.  Animal 
procedure protocols were approved by the Institutional Animal Care and Use 
Committees of either the University of Pennsylvania or the University of 
Massachusetts. 
 
AAV vectors 
Recombinant AAV2/9 vector expressing the human AAT (hAAT) gene or GFP 
and a miRNA under the transcriptional control of the CB promoter were 
generated, purified, and titered by the University of Massachusetts Gene 
Therapy Vector Core. 
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Virus instillations  
Orotracheal intubation 
Mice were anesthetized by isoflurane inhalation in a closed ventilation chamber. 
Once anesthetized mice were placed in dorsal recumbency on a rodent 
workstand (Braintree Scientific, Braintree MA) with their head extended using an 
incisor loop. The larynx was visualized using an otoscope (Welch Allen, Braintree 
Scientific, Braintree MA) and a 20 gauge 1.25 inch catheter (BD Angiocath, 
Becton Dickinson, Sandy Utah) placed with the assistance of a stylet. The 
intubation catheter was used to instill the AAV vector in 125µl total volume. 
Following instillation, mice received 2-3 ventilations with 0.2cc of air before the 
catheter was removed. Mice were monitored closely until fully recovered from 
anesthesia.  
 
Serum AAT ELISAs 
Human AAT ELISA 
High binding extra, 96-well plates (Immulon 4, cat# 3855 Dynatech Laboratories, 
Inc., Chantilly, VA) were coated with 100μl of goat anti-hAAT (1:500 diluted; cat# 
55111MP Biomedicals, irvine CA) in Voller's buffer overnight at 4°C. After 
blocking with 1% non-fat dry milk in PBS-Tween20, duplicate standard curves 
(hAAT; cat#16-16-011609, Athens Research and Technology, Athens, Georgia,) 
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and serially diluted unknown samples were incubated in the plate at room 
temperature for 1 hour. Following washing, 100ul of secondary antibody was 
applied, Goat anti-hAAT(HRP) (1:5000 diluted, cat # ab7635-5, Abcam Inc, 
Cambridge, MA) and the plate was incubated at room temperature for 1 hour. 
The plate was washed well with phosphate-buffered saline (PBS)-Tween 20 
between each step. After reaction with TMB peroxidase substrate (KPL, Inc, 
Gaithersburg, Maryland catalogue no. 50-76-00), the reaction was terminated by 
adding 50ul of 2N H2SO4 (cat# A300–500 Fisher, Pittsburg, PA). Plates were 
read at 450nm on a VersaMax microplate reader (Molecular Devices). 
 
Z-AAT ELISA 
High binding extra, 96-well plates (Immulon 4, cat# 3855 Dynatech Laboratories, 
Inc., Chantilly, VA) were coated with 100μl of Alpha-1-Antitrypsin-Z (1:100 diluted 
mouse-anti-human, clone F50.4.1 Monoclonal Antibody cat# MON5038, Cell 
Sciences Inc., Canton, MA). Standard curves were created using PIZ mouse 
serum with 5% BSA (cat# B4287 Sigma, St. Louis, MO). Serially diluted unknown 
samples (100ul volume) were incubated in the plate at 37°C for 1 hour, 100ul of a 
secondary antibody was applied as described for the standard human-AAT 
ELISA but incubated in 5% BSA instead and incubated in the plate at 37°C for 1 
hour.  The plate was washed well with phosphate-buffered saline (PBS)-Tween 
20 between each step. After reaction with TMB peroxidase substrate, the 
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reaction was terminated by adding 50ul of 2N H2SO4 and plates were read at 
450nm on a VersaMax microplate reader (Molecular Devices). 
 
Serum c-Myc ELISA  
c-Myc tag levels were quantified by a similar ELISA  to that described above with 
the difference being that plates were coated with a c-Myc antibody (1:1000 
diluted Goat anti-c-Myc , MA cat#AB19234 Abcam, Cambridge MA) overnight at 
4°C and then blocked with 5% BSA at 37°C for 1hr. Standard curves were 
generated from supernatants collected from c-Myc-AAT transfected cells.  
 
Liver and Lung Histology 
For determination of histological changes, samples were fixed in 10% neutral-
buffered formalin (Fisher Scientific), and embedded in paraffin. Immuno-
histochemistry for hAAT, was performed as previously described 66. Tissue 
sections (5 μm) were deparaffinized, rehydrated, and blocked for endogenous 
peroxidase with 3% hydrogen peroxide in methanol for 10 minutes. To detect 
hAAT expression, tissue sections were incubated with primary antibody [rabbit 
anti-human AAT (1:800; RDI/Fitzgerald Industries, Concord, MA)] overnight at 4 
°C. Staining was detected using ABC-Rb-HRP and DAB kits (Vector 
Laboratories, Burlingame, CA). 
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Quantitative PCR 
Vector biodistribution in AAV2/9.CB.double6xmiR-AAT oro-tracheally dosed mice 
was determined by TaqMan quantitative PCR as described previously 88. Briefly, 
primers and probes designed to target the CB promoter region of the construct 
were used. Data was analyzed using StepOne Software (Applied Biosystems, 
Carlsbad, California 92008), and vector genome (VG) copy number determined 
using a standard curve and normalized to genome copy number per 100ng of 
genomic DNA. 
Results 
Intratracheal delivery of AAV2/9 expressing miRNAs results in effective 
AAT knockdown in liver. 
We assessed the effectiveness of AAV9-mediated miRNA knockdown when 
vector was delivered to the airways of PiZ transgenic mice. Three artificial 
miRNAs based on the miR-155 backbone were designed to specifically target the 
coding sequence of hAAT gene and cloned in tandem at the intron of the CB 
promoter and again upstream of the poly-A region. In essence the cassettes 
contain two copies of each of the three miRNAs (6XmiR).  Briefly, groups of four-
eight 3-6 month old PiZ transgenic mice were given 1012 GC of AAV2/9.CB.GFP 
(control) or AAV2/9.CB.double6xmiR_GFP in 125µl and expression of PiZ in 
serum monitored every 14 days up to day 91 (the termination of the experiment).  
Typically, levels of PiZ in serum for 3-6 month-old PiZ transgenic mice are 
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between 200-400 µg/ml (Fig. 4.1A). When mice were given the control vector 
AAV2/9.CB.GFP, the serum levels of PiZ remained unchanged (Fig. 4.1A) and 
increased with time reaching 400 µg/ml by the end of the experiment (day 91) 
(Fig. 4.1A).  
 
Figure 4.1 Total alpha-1-antitrypsin levels  in PiZ mice decrease after tracheal 
delivery of rAAV9 encoding double-6XmiR GFP. A. Results of total human AAT 
ELISA comparing serum levels in rAAV9 double-6XmiR GFP and rAAV9 GFP (control) 
dosed animals. B. Percent knockdown of total AAT in rAAV9 double-6XmiR GFP dosed 
animals relative to rAAV9 GFP control animals. n=4 (rAAV9 double-6XmiR GFP ) n=8 
(rAAV9 GFP controls). 
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In stark contrast, for the PiZ mice that were treated with 
AAV2/9.CB.double6xmiR-GFP a significant knockdown (~80%) was observed as 
early as 14 days post instillation (Fig. 4.1B) and the knockdown effect was 
maintained for the duration of the experiment (Fig. 4.1B).  This sustained 
knockdown was also evident by liver histology at day 91, where mice treated with 
AAV2/9.CB.double6xmiR-GFP also had dramatically lower levels of Z-AAT in the 
livers as determined by immuno-staining (Fig. 4.2).  
A B
*
Figure 4.2 There is a significant reduction in hepatic human AAT staining of 
rAAV9 double-6XmiRNA dosed PiZ mice compared to rAAV9 GFP controls. A. 
Human AAT staining of liver in rAAV9 GFP dosed PiZ mice (20X magnification). B. 
Human AAT staining of liver in rAAV9 double-6XmiRNA dosed PiZ mice (20X 
magnification). C. Quantification of human AAT staining depicted in (A) and (B) 
(*P<0.0001) (n=4 in each group). 
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Dual-function rAAV9 vectors.   
The effective AAT knockdown in PiZ transgenic mouse liver (Fig. 4.1B)  following 
airway delivery of AAV9 vector expressing miRNAs targeting the liver prompted 
the next set of experiments using dual function vectors designed to augment M-
AAT both systemically and in the lungs while knocking down Z-AAT in the liver.   
Briefly, 4-5 month-old PiZ transgenic mice (n=8) were given 1012 GC of 
AAV2/9.CB.double6xmiR_AAT vector in 125µl and expression of PiZ in serum 
was monitored every two weeks for 91 days. Similar to the earlier findings using 
AAV9 vector expressing the miRNAs against M-AAT, these animals sustained 
reduction in circulating Z-AAT in the range of 80% (Figure 4.3A). Interestingly, we 
observed a simultaneous increase in serum circulating M-AAT  
  
While effective M-AAT systemic augmentation and knockdown of Z-AAT in the 
PiZ transgenic mouse liver was achieved following the oro-tracheal 
administration into the distal trachea of the AAV2/9.CB.double6xmiR-AAT vector 
it was also important to determine the effect of AAV2/9.CB.double6xmiR-AAT 
vector delivery and subsequent expression in the lung. As such, at the end of the 
study (day 91) we evaluated the level of M-AAT (c-myc) expression in the BAL 
fluid of PiZ transgenic mice (n=5) treated with 1012 GC in 125µl of 
AAV2/9.CB.double6xmiR-AAT or untreated controls. As demonstrated in Figure 
4.3B, expression of M-AAT was undetectable in the BAL fluid of the untreated 
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PiZ transgenic mice. In contrast, high expression of M-AAT was observed in the 
BAL fluid of PiZ transgenic mice (Fig. 4.4B).  
 
Figure 4.3 Simultaneous augmentation of wild-type (PiM) AAT and knockdown of 
mutant (PiZ) AAT following rAAV9 vector delivery. A. Augmentation of wild-type 
(PiM) AAT following rAAV9 double-6XmiRNA AAT vector administration in comparison 
to GFP (control) animals using a c-myc ELISA (upper graph). PiZ specific ELISA 
demonstrating knockdown of mutant (PiZ) AAT relative to GFP controls (lower graph). B. 
C-myc ELISA showing elevations in wild-type (PiM) AAT levels in the lungs of animals 
dosed with the vector compared to uninjected controls. C. Vector genomes present in 
several tissues. n=8 (Double-6XmiR AAT and GFP animals), n=5 (uninjected BAL 
controls) (P<0.0001). 
 
 
Next, I evaluated the biodistribution profile of AAV2/9 by real-time PCR (Figure 
4.3C). We found that the delivery of 1012vg of AAV2/9 in 125µl via the trachea 
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targets both lung and liver very efficiently, in fact there was higher transduction of 
the liver despite the airway delivery route (Figure 4.3C).    
 
Summary 
Gene therapy is being developed as a curative option for subjects with AAT 
deficiency. Rather than focusing on the expression of AAT in patients with AAT 
deficiency, gene transfer vectors are also designed to down-regulate the 
expression of the mutant gene. The most promising gene transfer vector for AAT 
deficiency is that based on AAV. Indeed, AAV serotypes 7, 8 and 9 have been 
demonstrated to be superior to any other vector for transducing the liver with 
exceptional efficiency. We have previously shown that systemic delivery AAV9 
vector- expression of miRNAs was effective at Z-AAT knockdown by ~80% 67. In 
this present study we took advantage of the biodistribution profile of AAV9 to 
non-invasively target the liver of PiZ transgenic mice. We demonstrate that 
delivery of 1012 GC of AAV9 instilled via the orotracheal route in relatively large 
volume of 125µl to the airways of PiZ transgenic mice was successful at 
transducing the liver and resulting in ~80% knockdown of circulating PiZ levels.  
AAV9 is a highly efficient vector that has been shown to effectively transduce a 
variety of different tissues in small and large animal models. Additionally, AAV9 
can transduce the liver when given IN 76. In our studies a large volume (125µl) of 
AAV9 vector was used which in combination with the anesthesia given to mice 
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for the instillation affects the wider distribution of the vector to the lower airways 
and allows for transcytosis of vector to occur.  
Our findings suggest that tracheal delivery of AAV2/9 is a non-invasive delivery 
method of therapeutic gene therapy vector to the liver and lung of patients with 
AAT deficiency. While the dose of the AAV9 vector used here to effectively 
knock-down mutant AAT was relatively high (1012 GC) the efficiency and 
persistence of knockdown achieved was impressive suggesting that a log-lower 
dose could be as effective for those disease states in which 100% knockdown of 
mutant gene expression is not necessary to result in a therapeutic benefit. 
Additionally, using a liver specific promoter such as the thyroxine-binding globulin 
promoter and a lower dose of AAV9 vector may allow improved targeting and 
transduction of the liver by the orotracheal route. Non-invasive vector delivery to 
target the liver is useful for various genetic diseases in which low level systemic 
protein expression by the liver can ameliorate symptoms.                                              
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CHAPTER V 
Muscle Delivery of AAV 
Introduction  
Adeno-associated virus vectors can efficiently transduce both cardiac and 
skeletal muscle through either local or systemic delivery. AAV1, AAV6, AAV7, 
AAV8 and AAV9 each have the ability to efficiently transduce muscle tissue, with 
multiple studies showing that cardiac transduction is most efficiently mediated by 
AAV9 89-91. AAV vectors are capable of targeting both dividing (myoblasts) and 
non-dividing (myofibers and cardiomyocytes) cells with long-term persistence, 
potentially for the life of the animal, possible in non-dividing cells.  
 
Targeting cardiac and skeletal muscle tissue in mice and rats allows for the 
development of therapeutic vectors for diseases ranging from muscular 
dystrophies, to Pompe disease, to disorders of fatty acid oxidation that effect 
both the heart and skeletal muscle. Potential cardiac gene therapy targets 
include a wide range of models of cardiomyopathy, both acute and chronic. 
Skeletal muscle, because of its large mass, has also been targeted to express 
non-muscle secreted proteins such as alpha-1 anti-trypsin, coagulation factor IX, 
apolipoprotein E and erythropoietin. It is also possible to transduce both the 
peripheral and central nervous tissue innervating a specific muscle group by 
retrograde transport following intramuscular delivery 92.  
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While direct delivery to the heart or specific skeletal muscle groups allows for 
transgene expression in the desired tissue with minimal vector genomes 
reaching other organs, many times systemic delivery of a vector to target multiple 
or all skeletal muscle groups in addition to the heart is desired. In this case 
systemic intravascular delivery may be necessary, but this carries with it the risk 
of expressing the transgene of interest in off-target organs, such as the liver. 
Specificity for muscle and heart following intravenous delivery can be increased 
by including a muscle specific promoter and/or enhancer in the transgene 
cassette 93,94. Another potential option for limiting transgene expression in organs 
other than the muscle would be to include microRNA binding sites in the 
transgene cassette that will mediate the binding of tissue specific microRNAs in 
order to suppress expression of the transgene in those tissues. For example, 
inclusion of a microRNA binding site for MiR-122 will silence expression in the 
liver 95. 
While all of the procedures described in this unit are scalable to large animal 
species such as dogs, pigs, and non-human primates, vector dosage becomes 
more of an issue because of the large amounts of vector required, especially for 
intravenous dosing. Local delivery such as intra-cardiac and limb vascular 
delivery can reduce the amount of vector required for adequately transducing the 
tissue in these larger species.96-98 It should be noted that the vector tropism 
found even in non-human primates (other than chimpanzees) may not correlate 
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to the vector tropism ultimately seen in humans when clinical trials are 
performed. 
 
Regional Limb Delivery of AAV 
Recombinant adeno-associated virus (rAAV) targets skeletal muscle readily and 
because myocytes are a non-dividing cell type, therapeutic proteins can be 
expressed long-term, despite low levels of chromosomal vector integration.99-103 
This makes muscle a good gene therapy target for both muscle specific disease 
and as a sight for production of secreted proteins.26,27,43,48,49,100,104-107 While direct 
intramuscular (IM) vector injections are effective in targeting muscle cells, the 
area of spread from the injection site is limited104,108, meaning that only a 
relatively small area of myocytes can be targeted in this manner without having 
to administer multiple IM injections per large muscle group and the need to dose 
each muscle group separately. Systemic intravascular delivery can target 
skeletal muscle effectively, but requires large amounts of vector and may 
increase exposure of non-target organs. This has led investigators to explore 
other means of delivering vector more widely to the muscle, while still limiting the 
amount of vector in the systemic circulation. This can be achieved through 
several different methods of infusing the limb vasculature with vector while it is 
isolated from systemic circulation, often through the use of a tourniquet or vessel 
clamps, allowing vector to access the muscle groups distal to the vessel 
occlusion. This technique has been adapted from procedures used to deliver 
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regional chemotherapy, anesthesia, and antibiotics to the limb109-113.  The goal is 
to either circulate the agent through the limb vasculature to allow extravasation or 
to increase the intravascular pressure/volume to create increased hydrodynamic 
pressure to expand vascular beds and perhaps increase the size and number of 
endothelial pores (either intracellular or intercellular)114-116. 
Regional limb delivery was initially described in the context of gene therapy as a 
method for delivering plasmid DNA (pDNA) constructs, rAAV, or adenovirus to 
myofibers via the arterial circulation using moderate to high volumes of fluid (with 
or without histamine and papaverine)108,116,117. Initial work was done using high 
volumes of fluid to deliver luciferase expressing pDNA into the femoral artery of 
rats with occlusion (10 minutes) of both the femoral artery and vein via vascular 
clamps117. Leaving the femoral vein unclamped or delivering the pDNA over a 
longer time decreased luciferase expression117. They later demonstrated that 
they could express full-length dystrophin in a Duchenne Muscular Dystrophy 
mouse model using a similar procedure118. This method was also shown to be 
translatable into larger animal models, including rhesus macaques and 
pigs119,120. Interestingly the work in pigs demonstrated a decreased transgene 
expression in muscles with higher intramuscular pressure during the pDNA 
delivery. The author’s hypothesized that the increased intramuscular pressure, 
due to muscle edema, may have led to the collapse of small caliber vessels 
within the muscle, decreasing extravasation of the pDNA120. They noted that the 
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best pDNA expression was in muscle groups where the muscle compartment 
pressure did not exceed the diastolic blood pressure.   
Initial work with rAAV (expressing sarcoglycan) in a hamster model of limb-girdle 
muscular dystrophy used a femoral artery infusion with tourniqueting of the limb 
and clamping of both the femoral artery and vein108. The rAAV dose was 7x1011 
vector particles (VP)/animal (in 500ul of PBS) delivered after perfusion with 
papaverine and histamine (500ul volume). The vector was followed by a chase of 
1ml/100g of PBS and the limb was flushed with 3ml of PBS to remove residual 
papaverine, histamine and vector via the venous catheter108. This infusion 
procedure leads to widespread sarcoglycan expression throughout the hindlimb 
of the hamster.  
Subsequent to these early studies several groups have worked to optimize 
muscle rAAV delivery using differing methods of regional limb infusion. In this 
review we will summarize many of these studies, particularly those that utilized 
large animal models, and detail the methods that were used (Table 5.1). 
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Arterial Delivery of rAAV to Large Animal Models 
 
The first large animal study to look at local arterial delivery of an rAAV vector 
involved delivery of an rAAV2 encoding the lacZ reporter gene or the canine 
factor IX (cFIX) gene delivered to a hemophilia B dog model104. This study 
involved the placement of an arterial catheter and simultaneous proximal thigh 
tourniquets with femoral artery and vein clamps. A dose of the vasodilator 
papaverine along with histamine, to promote vascular leakage (diluted in 2.5 
ml/kg of phosphate buffered saline (PBS)), was delivered prior to vector 
administration. The vector was diluted in 2.5ml/kg of PBS (with histamine) 
followed by a 10ml/kg bolus of PBS with a 15-20 minutes dwell time. Prior to 
tourniquet release an addition flush of 15ml/kg was administered. Following lacZ 
delivery no transgene expression was obtained and the author’s suspected an 
immune response to the transgene and subsequently delivered vector 
expressing the canine FIX gene, which according to their experience was fully 
tolerated in dogs. Following IM injection the cFIX expression was confined to the 
injection sight, however after limb infusion they detected widespread cFIX 
expression throughout the musculature of the limb supplied by the infused 
vessel104. This study not only demonstrated widespread muscle expression of 
cFIX in normal dogs but also clinical, long-term expression of therapeutic cFIX 
levels in hemophiliac dogs along with a dramatic reduction in episodes of 
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bleeding (2 episodes in 74 total months versus an expected 34 episodes over the 
same time period in untreated dogs). 
A 2nd study to employ a similar methodology involved delivery of a micro-
dystrophin gene to a muscular dystrophy mouse model using either rAAV1, 
rAAV6, or rAAV8 into the femoral artery 98. Interestingly, rAAV6 and rAAV8 had 
good levels of transduction, but the rAAV1 transduction efficiency was very low 
comparatively, a sharp contrast to the transduction with rAAV1 following IM 
delivery. Based on the mouse results, a large animal model study was carried out 
using rAAV8-eGFP (enhanced green florescent protein) delivery to 
Cynamologous macaques via the femoral artery (catheter to the level of the 
knee) to the calf muscles 98.  Widespread eGFP expression was seen throughout 
the lower limb with up to 86.4% of the muscle expressing eGFP in the soleus 
muscle. Subsequent work by this group has shown persistent rAAV8 micro-
dystrophin expression in the gastrocnemius of rhesus macaques following 
femoral artery catheterization and passage of the catheter to the level of the sural 
artery (tourniquets were placed proximal and distal to the gastrocnemius muscle) 
without the use of papaverine or histamine 121. A detailed procedural methods 
chapter for this technique was published in 201159. The same method was also 
used to deliver rAAVrh74 encoding either MCK.GALGT2 (stimulates dystrophin 
and lamimin alpha2 surrogate expression) or microdystrophin to the 
gastrocnemius muscle of rhesus macaques56,122.  
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A study looking at rAAV6 encoding a human alkaline phosphatase (hPLAP) gene 
delivery to the canine pelvic limb via the femoral artery compared transgene 
expression with or without limb exsanguination (using a limb compression 
wrapping technique) prior to vector delivery found that expression levels were 
highest with prior limb exsanguination 123. Expression levels were lower if the 
compression wrap was left in place for the duration of the vector dwell time 
versus removal prior to vector infusion. This study did not report the use of 
papaverine or histamine in association with the vector delivery. 
Together, these studies indicate that femoral artery vector delivery with rAAV6, 
rAAV8, or rAAVrh74 with or without prior limb exaguination can result in 
widespread transduction of the lower limb musculature even without the use of 
papaverine or histamine. The safety and efficacy of this method have yet to be 
published in human subjects but with its similarity to widely used limb infusion 
techniques applied in humans; it is likely that it will prove generally safe. 
 
Peripheral Intravascular Hydrodynamic Delivery of rAAV to Large Animal 
Models 
 
A method to deliver rAAV diluted in a moderate volume of fluid retrograde from a 
peripheral limb vein without the use of histamine or papaverine was published in 
rats and dogs and simplified the arterial and venous delivery methods described 
in the introduction for pDNA delivery114. The group termed this method “afferent 
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transvenular retrograde extravasation (ATVRX).” For this method in the dog, a 
catheter was placed in the greater saphenous vein; a tourniquet was placed at 
groin level and tightened until the femoral pulse was no longer palpable. The 
vector was then delivered in 500ml of PBS with standard intravenous tubing and 
a pressure bag at a pressure of 300mmHg114. The ATVRX method has the 
advantage of being simple to execute, which decreases anesthesia time, and 
does not pose the same potential risks as arterial delivery (thrombosis, emboli 
etc) and vascular modifying agents such as histamine, heparin and papaverine.  
Using ATVRX, the authors were able to obtain high levels of reporter gene 
expression throughout the dosed limbs in both rats and dogs 114. The level of 
expression was dependent on delivery pressure (<50mmHg had lower 
transduction, 100 and 400mmHg resulted in uniform transduction) but was not 
dependent on dwell time prior to tourniquet release. The author’s reported no 
adverse clinical or histological side-effects of the procedure.  
The ATVRX technique was then applied in non-human primates (cynomolgus 
macaques) to compare rAAV1 versus rAAV8 transduction, biodistribution and 
transgene expression 55. There were increased numbers of vector genomes, and 
subsequently increased transgene expression, in the muscle following rAAV1 
regional limb infusion versus rAAV8; however the pattern of distribution was 
similar. Further work by the same group, also in cynomolgus macaques, 
demonstrated that they could get long-term muscle expression, without 
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immunosuppression, of cynomolgus macaque erythropoietin following regional 
limb infusion, in contrast to IM dosing, where expression was quickly lost61. 
This same hydrodynamic delivery method was used in dogs with hemophilia B to 
deliver rAAV2 expressing canine factor IX (cFIX) without the use of papaverine or 
histamine 124. With the use of transient immune suppression (to prevent antibody 
formation against cFIX) they were able to demonstrate long-term cFIX 
expression that translated to improved clotting time and markedly fewer bleeding 
episodes in the treated dogs. A concurrent safety study in hemophilia B dogs 
further demonstrated increased expression of cFIX following limb infusion when 
compared to IM administration125. They also demonstrated immune responses to 
the cFIX transgene (IgG2 antibodies) and the presence of a CD4+Il-10+FoxP3+ T-
cell population (regulatory T cells) that likely contributed to the sustained cFIX 
transgene expression. They postulated that the transient immunosuppression 
used may have played a role in the expansion of the regulatory T cells that was 
observed.  
In order to asses venous local regional delivery in a model of muscle disease as 
a therapeutic proof of concept the ATVRX method was applied to the forelimb of 
a canine Duchenne muscular dystrophy model126. This study supported safety of 
the delivery method and a high level of muscle expression at a dose of 
5x1013vg/kg delivered in either 20% or 40% of the limb volume.  With this dose 
and volume they were able to detect positive muscle fibers ranging from a mean 
per group of 58-76%, with a therapeutic threshold of >40%.  The higher the 
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vector dose delivered, the higher the expression they were able to detect at 
sights other than the injected limb (uninjected limb and diaphragm).   
Two studies have looked a high-pressure transvenous limb perfusion delivery of 
0.9% saline to both the pelvic and thoracic limbs of human muscular dystrophy 
patients57,58. The pelvic limb study infused saline volumes up to 20% of limb 
volume without adverse events beyond transient increases in muscle 
compartment pressures and short-term depression of limb tissue oximetry 57. For 
the thoracic limb study they evaluated saline volumes up to 43% of limb volume 
with no adverse events up to 35% of limb volume, other than the transients 
decreases in tissue oxygenation (returned to baseline within 5 minutes) and 
increased muscle compartment pressure (returned to baseline within 15 minutes) 
and a short-term decrease in compound muscle action potentials in a patient 
receiving 40% of limb volume 58. No clinical adverse events were reported.  
These studies, along with the pilot data in muscular dystrophy dogs, indicate that 
this is a clinically feasible route and method for gene therapy in muscular 
dystrophy patients. 
  
Summary 
 
Over the past decade, methods for regional limb infusion to deliver gene therapy 
to the skeletal muscle have shown effectiveness in increasing expression over IM 
delivery. The technical aspects of delivery have also improved as investigators 
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have attemped to simplify both the arterial and venous delivery methodolgies in 
order to move them toward clinical applicability. The true test of the usefullness 
of these techniques will come as they are employed in human clinical trials. 
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CHAPTER VI 
Regional Limb Infusion in Rhesus 
 
Introduction 
 
In this chapter I will present data from a regional limb infusion trial in rhesus 
macaques. This study was a continuation of the clinical AATD trials described in 
Chapter III and builds on the limb infusion background in Chapter V. As I 
discussed in Chapter III, the last AATD clinical trial showed a dose response in 
AAT serum levels but levels remained approximately 2.5% of target serum levels 
following intramuscular injection. These levels remained steady at this level 5 
years after dosing (Figure 6.1). Based on the data presented in Chapter V that 
expression levels are similar or increased following limb perfusion, while the level 
that can be delivered is higher, we hypothesized that limb perfusion delivery 
would result in higher serum levels than the same dose of AAV vector delivered 
intramuscularly.  
For this study we compared both an intravenous hydrodynamic (HPV) and an 
intra-arterial push and dwell balloon catheter method (IAPD) and compared the 
serum AAT levels and immune responses to those seen with an intra-muscular 
(IM) injection of the same dose of vector.  
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Figure 6.1 M-AAT Serum Levels over the 5 years after intramuscular 
administration of rAAV1-CB-hAAT. The dotted line is at ~2.5% of the target 
therapeutic serum concentration of 572ug/ml (11uM). Serum AAT levels were assayed 
using a PiM-specific ELISA. The high dose was 6.0 x 1012 vg/kg, the mid dose was 1.9 x 
1012 vg/kg and the low dose was 6.0 x 1011 vg/kg.  
 
 
Methods 
Study Outline 
Animals were selected based on serum neutralizing antibodies against AAV1 or 
AAV8 as determined commercially by the UMass Gene Therapy Vector Core 
using an in-vitro assay (Table 1.1). Five groups of animals will be administered 
rAAV1-CB-rhAATmyc or rAAV8-CB-rhAATmyc by IM, IAPD, or HPV as assigned 
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(Table 6.1) on Study Day (SD) 0.  The vector dose will be 6x1012vg/kg for all 
groups.  
Skeletal muscles (Quadriceps and Gastrocnemius) and liver will be collected 
from two spare/training naïve animals or biopsied from two study animals prior to 
vector administration. The tissue biopsies will be analyzed as baseline for 
multiple endpoints (Table 6.2).  
After dosing, animals were monitored by veterinary staff twice daily for 7 days for 
pain, bleeding, suture loss, limping, or other signs. Detailed clinical observations 
and body weight were recorded. Blood was collected and tissues biopsied for 
endpoint analyses as outlined in Tables 6.3. At SD 60, animals were euthanized 
and subject to a complete necropsy and blood and tissues collected for 
evaluation.  
Vector Dosing 
Test Article Preparation    
The vector was administered in volumes dictated by the injection or infusion 
procedure (Table 6.1).  For each administration route, individual stock vials of 
vector were thawed and diluted on the day of use in the appropriate 
concentration and volume to deliver the targeted vector dose (6 × 1012 vg/kg). 
The vector was diluted with Lactated Ringer’s Solution.  
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Table 6.1  Rhesus Limb Infusion Experimental Design a 
Dose 
Group 
 
Animal ID  
(Sex; NAb titer) 
b
 
Test Article 
(6x10
12 
vg/kg for all 
groups) 
Route 
c
 Dosing volume 
1 
 
RA1683 (F; 1:5) 
RA1598 (M; 1:10) 
rAAV1-CB-
rhAATmyc 
IM 
d
 
0.5mL/injection  
(8 injections) 
d
  
2 
 
RA1709 (F; 1:5) 
RA1562 (M; 1:10) 
rAAV1-CB-
rhAATmyc 
IAPD 
12.5mL/kg 
3 
 
RA1660 (F; 1:10) 
RA1664 (F; 1:10) 
rAAV8-CB-
rhAATmyc 
IAPD 
12.5mL/kg 
4 
 
RA0770 (F; <1:5) 
RA1567 (M; 1:10) 
rAAV1-CB-
rhAATmyc 
HPV 
50mL/kg 
5 
 
RA1676 (F; 1:10) 
RA1703 (F; 1:10) 
rAAV8-CB-
rhAATmyc 
HPV 
50mL/kg 
a All animals will be euthanized at SD 603 
b Anti-AAV1 NAb for groups 1, 2 and 4 and anti-AAV8 NAb for groups 3 and 5;  
c All dosing will be performed in the right hind limb  
d Intramuscular dosing will be performed at a total of eight injections, four into right 
quadriceps and four into right Gastrocnemius 
e Concentration is calculated based on a 5 kg animal. Vector concentration will be 
adjusted to achieve the dose for each animal based on its actual body weight 
 
Intramuscular Injection (Group 1) 
The animals were anesthetized with ketamine (10 mg/kg with 2-3mg/kg bumps 
as needed) administered intramuscularly.  For the IM dose group, rAAV1-CB-
rhAATmyc vector was administered as eight, 0.5 mL injections (i.e. 4 mL of total 
dose volume), with the concentration adjusted to achieve the desired total dose 
based on the body weight of an animal. The injections were performed into the 
quadriceps and gastrocnemius muscles in the right hind limb with 4 injections in 
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each muscle.  The spacing between injections depended on the size of the 
muscle, but were 0.5 to 1 cm apart. Post injection pain, if observed, was 
managed with buprenorphine (0.01 -0.03 mg/kg) administered IM. Thereafter, 
buprenorphine (0.01 to 0.03 mg/kg, IM) was administered as needed, based on 
clinical observations.   
 
Table 6.2 Endpoints analyses in tissue biopsies 
Tissue Endpoint Time points 
Quadriceps and 
Gastrocnemius 
muscle (from either 
leg for baseline and 
from both legs on SD 
21) 
qPCR for Vector Genomes 
Baseline (2 
animals) and 
Day 21 (all 
study animals) 
Immunology and capsid 
staining 
rhAAT expression by IHC 
Liver rhAAT expression by IHC 
Baseline (2 
animals) 
 
 
Intravascular Limb Infusion  
 
i. Pre-surgical Preparation and Anesthesia 
Aseptic technique was used throughout the surgical procedure for the IAPD and 
HPV delivery. For surgical procedures animals were pre-medicated with 
ketamine (10 mg/kg) administered intramuscularly. Inhalant anesthesia 
(generally 1 - 4% isoflurane in oxygen for induction and 0.5 % to 3% isoflurane in 
oxygen as needed for maintenance) were administered via face mask to facilitate 
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intubation. During the operative procedure anesthesia was maintained with 0.5% 
to 3% isoflurane in oxygen administered via the endotracheal tube.  
One or two venous catheters were placed in a peripheral vein in the leg or arm 
(not the leg for the infusion).  The catheters were used, as needed, to inject 
heparin and protamine, to withdraw blood for assessment of clotting time, to 
provide Plasmalyte (5 mL/kg/hr) during the infusion procedure. 
 
Table 6.3 Rhesus Study Endpoints analyses in blood/serum 
Sample Endpoint Time points 
Whole Blood (EDTA) Hematology Pre-study 
Serum Serum chemistry  Pre-study, SDs 1, 7, 14, 21 
and 60 
Whole Blood  Active Clotting Time (ACT) 
During the infusion 
procedure  
Whole Blood (EDTA) qPCR for Vector Genomes Baseline, 10, 20 and 30 
minutes after vector 
administration and on SDs 
1, 7, 21, and 60 
Whole Blood 
(heparinized) 
PBMC isolation/ELISPOT Baseline, SDs 14, 21 and 60 
Serum  rhAATmyc level by ELISA Baseline and SDs 7, 14, 21 
and 60 
Serum Neutralizing anti-AAV1 and 
anti-AAV8 antibodies  
Baseline a and SDs 0, 7, 14, 
21 and 60 (terminal) 
a Baseline samples are provided by Covance as a prestudy screen. For baseline 
samples, both anti-AAV1 and anti-AAV8 are analyzed, and for the remaining time points 
anti-AAV1 is analyzed for samples from Groups 1, 2 and 4 and anti-AAV8 analyzed for 
Groups 3 and 5. 
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ii. Intra-Arterial Push and Dwell (Groups 2 and 3) 
Group 2 and 3 animals received the vector (rAAV1-CB-rhAATmyc for Group 2 
and rAAV8-CB-rhAATmyc for Group 3) in a volume of 12.5mL/kg by IAPD 
infusion.  
Buprenorphine (0.01 to 0.03 mg/kg, administered IM) was given preemptively at 
least 20 minutes prior to incising skin. The surgical site was prepared according 
to LRRI SOP 1275, Performance of Nonhuman Primate Surgery. After lidocaine 
(1 mg/kg) and bupivacaine (1 mg/kg) were administered by local application at 
the incision site, an incision was made in the lower anterior thigh of the right 
pelvic limb and the superficial femoral artery and vein dissected and isolated with 
silk suture. Arterial and venous access was obtained with sheath catheters. The 
catheters were inserted by cut-down and then retrograde positioned into upper 
femoral artery and vein near inguinal ligament. The arterial and venous balloon 
catheters were then placed through their respective sheathes. The stopcock on 
the venous catheter was turned to prevent venous outflow. Correct placement of 
the catheters were checked by x-ray (fluoroscopy), confirming the presence of 
the arterial and venous balloons above the level of the vascular branches leading 
to the quadriceps muscle groups. Once the vein and artery were cannulated, 
heparin was administered to achieve an activated clotting time of >350 sec 
determined using an i-STAT clinical analyzer and an activated clotting time (ACT) 
cartridge. The limb was elevated and wrapped tightly to massage all venous 
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blood from the limb, after which the catheter balloons were inflated to prevent the 
vascular flow of the femoral vein and artery.  The limb was then lowered and 
unwrapped. After a pre-flush with LRS (5ml/kg), the vector (rAAV1-CB-rhAATmyc 
for group 2 and rAAV8-CB-rhAATmyc for group 3) in a volume of 12.5mL/kg was 
infused as quickly as possible though the arterial catheter sheath port. The vector 
solution was allowed to dwell for 15 minutes after which repeat fluoroscopy 
confirmed that the balloons had remained inflated through the entire dwell time. 
At that point a post-flush of 5ml/kg of LRS will be injected into the arterial 
catheter. After the infusion had been completed, the balloons were deflated and 
catheters removed. The effects of the circulating heparin were reversed by 
injection of protamine (0.5-1 mg/100 USP heparin units administered).  Blood 
samples were obtained and clotting time checked.  When the clotting time had 
returned to near baseline value (±20 seconds), the animal was allowed to 
recover from anesthesia and returned to its home cage. 
 
Hydrodynamic Peripheral Vein delivery (Group 4 and 5) 
Group 4 and 5 animals received the vector (rAAV1-CB-rhAATmyc for Group 4 
and rAAV8-CB-rhAATmyc for Group 5) in a volume of 50mL/kg by HPV infusion.  
For the HPV, an intravenous catheter was placed into the distal peripheral 
saphenous vein of the right pelvic limb. The limb was elevated and wrapped 
tightly from distal to proximal (from just above catheter to mid thigh) to massage 
as much blood as possible from the limb. A tourniquet was then placed around 
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the level of the proximal thigh and tightened to prevent vascular flow into and out 
of the limb. The limb was then lowered and unwrapped. The vector (rAAV1-CB-
rhAATmyc for group 4 and rAAV8-CB-rhAATmyc for group 5) in a volume of 
50ml/kg was infused over about 5 minutes. The tourniquet remained tight for 15 
minutes following the infusion and was then released. The catheter was removed 
and the animal allowed to recover from anesthesia and returned to its home 
cage.  
 
Physiological Parameter Monitoring During Infusions 
Heart rate, respiratory rate and body temperature were monitored and 
documented during the surgical procedure to evaluate the status of animals.   
 
Post-operative pain management 
Post-operative pain was managed with buprenorphine (0.01 -0.03 mg/kg 
administered IM at least 6 hours after the initial dose. Carprofen, 2 mg/kg was 
administered subcutaneously (SC) or intramuscularly just after the surgery before 
the animal has fully recovered from anesthesia.  Thereafter, buprenorphine (0.01 
to 0.03 mg/kg, IM, one dose) and/or carprofen (2 mg/kg, IM or SC) was 
administered as needed after the surgery, based on clinical observations.  
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Post Vector Administration Monitoring and Observations 
After vector administration on the dosing day, animals subjected to infusion 
procedures (Groups 2-5) were observed for evidence of erythema and edema of 
the infused site, blood vessel rupture, compartment syndrome, traumatic 
rhabodomyolysis, high intravascular pressure, bleeding (hematoma), pain, 
abnormal gait limping, potential damage to nerves, muscles or the vascular 
network.  
In addition, after vector administration all animals (Groups 1-5) were monitored 
for clinical signs twice daily for 7 days. Behavioral and clinical observations were 
made on awake animals, with special attention paid to the legs and any abnormal 
motor movements (including posture or gait abnormalities). 
 
Pre-study Physical Examinations and Measurements  
A clinical veterinarian experienced in the care of nonhuman primates performed 
comprehensive physical examinations of each animal after quarantine release 
and prior to study initiation. The examination included evaluations of behavioral 
and clinical observations, body weight, rectal temperature, respiratory and heart 
rate, and a complete blood count (CBC) and serum chemistry screen.  
For CBC analyses, blood was collected by venipuncture of a peripheral vein. 
Samples were analyzed by ADVIATM 120 Hematology System (Siemens 
77 
 
 
Medical Solutions Diagnostics, Tarrytown, NY). Parameters for hematology are 
shown in Table 6.4.  
 
 
Table 6.4 Hematology Parameters Tested 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For serum chemistry analyses, blood was collected into a serum separator or clot 
tubes for centrifugation to separate cellular and serum fractions. Serum 
chemistry was determined using a Hitachi Modular Analytics Clinical Chemistry 
System (Roche Diagnostics, Indianapolis, IN).  The clinical chemistry parameters 
were measured as shown in Table 6.5.   
       Analyte                                                   Units 
Red Blood Cell Count 
Total White Blood Cell Count 
106/µL 
103/µL 
Hemoglobin g/dL 
Hematocrit % 
Mean Corpuscular Volume fL 
Mean Corpuscular Hemoglobin Concentration g/dL 
Mean Corpuscular Hemoglobin pg 
Platelet Count 103/µL 
Neutrophils % WBC 
Lymphocytes % WBC 
Monocytes % WBC 
Eosinophils % WBC 
Basophils % WBC 
Large Unstained Cells % WBC 
Neutrophils 103/µL 
Lymphocytes 103/µL 
Monocytes 103/µL 
Eosinophils 103/µL 
Basophils 103/µL 
Large Unstained Cells 103/µL 
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Table 6.5 Serum Chemistry Parameters Tested 
Analyte  Units 
Alanine Transaminase (Aminotransferase) 
– Serum 
 IU/L 
Albumin  g/dL 
Alkaline Phosphatase  IU/L 
Aspartate Transaminase 
(Aminotransferase)  – Serum 
 IU/L 
Blood Urea Nitrogen  mg/dL 
Bilirubin (Total)  mg/dL 
Calcium  mg/dL 
Chloride (Serum)  mmol/L 
Cholesterol (Total)  mg/dL 
Creatinine (Serum)  mg/dL 
Glucose  mg/dL 
   
Lactate dehydrogenase  IU/L 
Myoglobin  µg/mL 
Phosphorous  mg/dL 
Potassium (Serum)  mmol/L 
Protein (Total)  g/dL 
Sodium (Serum)  mmol/L 
Creatine Kinase   IU/L 
   
 
 
Serum c-myc ELISA 
High binding extra, 96-well plates (Immulon 4, cat# 3855 Dynatech Laboratories, 
Inc., Chantilly, VA) were coated with c-Myc antibody (1:1000 diluted Goat anti-c-
Myc , MA cat#AB19234 Abcam, Cambridge MA). Standard curves were created 
using RAG mouse serum that had been injected with AATc-myc and their AAT 
levels quantified using a total AAT ELISA. Serially diluted unknown samples were 
incubated in the plate at 37°C for 1hr, a secondary AAT antibody (Goat anti-
hAAT(HRP) 1:5000 diluted, cat # ab7635-5, Abcam Inc, Cambridge, MA) was 
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applied in 5% BSA and incubated in the plate at 37°C for 1hr.  The plate was 
washed well with phosphate-buffered saline (PBS)-Tween 20 between each step. 
After reaction with TMB peroxidase substrate, the reaction was terminated by 
adding 2N H2SO4 and plates were read at 450nm on a VersaMax microplate 
reader (Molecular Devices). 
 
Immune Cell Isolation from Muscle 
The rhesus muscle biopsy sample was cut into approximately 5mm3 pieces and 
incubated in RPMI media supplemented with DNase I (62.5U/ml, Zymoresearch) 
and collagenase (0.25mg/ml, Roche) for 2 hours at 37°C. Cell suspension was 
homogenized and filtered using a 70μm cell strainer before staining. Regulatory 
T cell populations were analyzed using CD3/CD4/Helios/FoxP3/CD25/OX40 
markers. Extracellular staining consisted of cell incubation on ice for 30 minutes. 
Cells were then washed twice with 1X PBS and re-suspended in 1X PBS 
supplemented with 0.5% FBS and 2mM EDTA. FoxP3 and Helios intracellular 
staining was performed according to manufacturer’s recommendations (anti-
human FoxP3 Flow kit, Biolegend). Cells were acquired using a FACS-LSRII flow 
cytometer (BD Bioscience) and analyzed with FlowJo software (version 10.1; 
Tree Star Inc). 
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IFNγ-ELISpot response to AAV1 and AAV8 capsids 
PBMCs were isolated before dosing and at day 60 post-injection and stimulated 
in vitro in R10 media supplemented with human IL2 and IL7 (1ng/ml) and a 
complete set of AAV1 or AAV8 peptides (0.5μg/ml) for 3 days. Then, cells were 
washed and resuspended in R10 media supplemented with human IL2 and IL7 
(1ng/ml) for 3 additional days. On day 6, cells were washed and left to rest 
overnight in R10 media. On day 7, the IFNγ-ELISpot assay was performed 
according to manufacturer’s recommendations (Monkey IFNγ ELISpotBASIC, 
MABTech). PBMCs were stimulated in vitro with overlapping peptides spanning 
the AAV1 or AAV8 capsid VP1 sequences, and divided into 3 pools (15-mers 
overlapping by 10 aa). A negative control consisted of unstimulated cells 
(medium only) whereas CD3/CD28 stimulation was used as a positive control for 
cytokine secretion. Responses were considered positive when the number of 
spot-forming units (SFU) per 106 cells were >50 and at least 3-fold higher than 
the control condition (*). 
Results 
Limb Infusion Procedures 
All animals tolerated both procedures well and recovered without incidence. The 
IAPD procedure had a total procedure time of around 4 hours and required three 
surgical personnel, one anesthetist, and two technical assistants to perform. The 
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HPV procedure had a total procedure time of around 1 hour and required two 
technical assistants and one anesthetist to perform. The increased procedural 
time with the IAPD procedure resulted from the time to place the catheters 
surgically and the time to confirm catheter placement by fluoroscopy. Marked 
limb swelling was seen following the HPV procedure but this resolved completely 
within 12-24 hours post-procedure and did not alter the animal’s ability to use the 
limb normally (Figure 6.2). 
 
Figure 6.2 Appearance of Rhesus Limbs During Vector Dwell Time. A. HPV injected 
animal (Top to Bottom) at beginning of vector injection, 5 minutes into delivery, 10 
minutes into delivery, and 2 minutes after infusion complete. B. During IAPD vector dwell 
time.  
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Serum c-myc ELISA 
We observed serum c-myc levels rise in all injection groups with both AAV1 and 
AAV8 capsids. While there was no statistically significant difference in serum 
level between the groups, the AAV1 hydrodynamic group trended the highest 
(Figure 6.3). 
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Figure 6.3 Serum c-myc levels following rAAV Rhesus AAT-c-myc delivery.  n = 2 
animals per group. 
 
Serum Creatine Kinase 
We saw a moderate spike in serum creatine kinase, a marker of muscle damage, 
1 day after delivery and a mild spike 21 days after AAV1 IAPD delivery (Figure 
6.4). At day 1 all other groups had only a mild to no increase in creatine kinase. 
The IM group had a very mild increase in CK in one animal at day 21. There 
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were no other serum chemistry or complete blood counts that changed 
significantly following vector dosing.  
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Figure 6.4 Serum creatine kinase levels following rAAV Rhesus AAT-c-myc 
delivery. IM = Intramuscular. AAV1 and AAV8 = AAV capsid type delivered. n = 2 per 
group. 
 
Immune Infiltrates in AAV1 Injected Muscle  
At day 60 post injection we were able to detect immune infiltrates in the IM 
injected animals. The lymphocyte cell population based on flow cytometry was 
32.3% CD3+CD4+ double positive. Of the CD4+ cells, 7.67% were also double 
positive for FoxP3 and Helios, consistent with a T-regulatory cell population 
(Figure 6.5).  
In the animals dose with AAV1 vector by IM, IAPD, and HPV delivery we 
quantified the cellular population within the muscle via flow cytometry (Figure 
6.6). The T cell population within the IM group was the highest percentage with a 
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mild increase following vector delivery. Following vector delivery we observed 
minimal to no T lymphocytes in the IAPD group. There was a small increase in 
both CD4 and CD8 cells following vector delivery in 1 of the HPV injected 
animals.  
 
 
Figure 6.5 Immune Cell Infiltrates in Intra-Muscular Injected Animals. Muscle was 
harvested at Day 60 post dosing with AAV1-CB-RhesusC-Myc. CD4+ T cells were gated 
based on double positive staining for CD3 and CD4. T-regulatory cells were gated on 
double positive staining for Helios and FoxP3 in the CD3+CD4+ population. n = 2 
animals. 
 
 
85 
 
 
IFNγ-ELISpot response to AAV1 and AAV8 capsids 
In animals dosed with AAV1 we saw a mild positive ELISpot response in one 
IAPD injected animal but only at baseline, not day 60 (Figure 6.7). In animals 
dosed with AAV8 we saw a mild ELISPot response directed at the capsid in both 
IAPD dosed animals, but not the HPV dosed animals. One of the animals only 
had the response at baseline, but not Day 60. The other animals had a mild 
response to capsid pool A at day 60. It should be noted that all the animals with a 
ELISPot response to capsid also have neutralizing antibodies present prior to 
vector dosing.  
 
Summary 
We found that both limb infusion techniques resulted in serum AAT levels 
comparable to those of IM injection with minimal morbidity in the dosed animals. 
The HPV procedure was technically simpler without the potential risks for 
morbidity/mortality that could result from the IAPD procedure such as prolonged 
anesthesia and infarctive emboli as the result of the arterial catheter. Based on 
the previous human trial resulting in AAV blood levels at ~2.5% of our therapeutic 
target we would want to aim for a 10-fold increase in vector delivery in the next 
phase of the clinical trial. If this were to be accomplished using intra-muscular 
injections it would require approximately 1000 injections per patient (1350ml of 
vector). While this would be technically possible it would be psychologically 
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dampening to study participation. Based on the fact that we were able to safely 
deliver 50ml/kg of volume to the HPV dosed animals (around 500ml per animal) it 
can be imagined that it would be easy to deliver the 1350ml volume necessary to 
provide 10-fold increase over the previous trial high-dose without even coming 
close to the 50ml/kg volume delivered in the rhesus (50ml/kg in an 80kg/176lb 
human is 4000ml).  
 
 
Figure 6.6 Percentage of T-cells in the muscle before and after vector delivery by 
intramuscular (IM), intra-arterial push and dwell (IAPD) and hydrodynamic delivery 
(HPV).  
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The immune cell infiltrates seen in the intra-muscularly injected animals, 
particularly the percentage of T-regulatory cells are similar to the percentage 
seen in the muscle of patients following IM AAV1-CB-AAT vector delivery. As 
discussed in Chapter III, we have hypothesized that this T-regulatory cell 
population is crucial to long-term gene expression 54.  
 
 
Figure 6.7 Interferon Gamma (IFNγ) AAV1 ELISPOT Results. Compared Day 0 and 
Day 60 after vector dosing. Peripheral blood mononuclear cells were cultured 6 days 
before a 48 hour restimulation with AAV1 peptide pool. Comparing intramuscular (IM), 
intra-arterial push and dwell (IAPD) and hydrodynamic delivery (HPV) animals. Each 
graph represents a single animal. * = denotes a positive response. CD3/CD28 = positive 
control. Control = media only negative control. 
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Figure 6.8 Interferon Gamma (IFNγ) AAV8 ELISPOT Results. Compared Day 0 and 
Day 60 after vector dosing. Peripheral blood mononuclear cells were cultured 6 days 
before a 48 hour restimulation with AAV8 peptide pool. Comparing intramuscular (IM), 
intra-arterial push and dwell (IAPD) and hydrodynamic delivery (HPV) animals. Each 
graph represents a single animal. * = denotes a positive response. CD3/CD28 = positive 
control. Control = media only negative control. 
 
Because of the low numbers of immune cells infiltrating the muscle in the IAPD 
and HPV dosed animals, we were not able to quantify the T-regulatory cell 
populations in those animals. The decreased immune infiltrate/response has 
been reported previously and was discussed in more detail in Chapter V 61. This 
lack of immune response to the vector allowed for sustained transgene 
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expression in the Toromanoff paper 55; however we are not sure what affect a 
decreased immune response will have on long-term AAT expression in patients.  
Overall, this data has shown the hydrodynamic limb infusion technique is safe, 
technically feasible and results in the same or slightly higher serum AAT levels 
when compared to intra-muscular dosing.  In the context of planning the next 
clinical trial of muscle-based rAAV1-AAT gene therapy, the equivalent safety and 
efficacy between hydrodynamic limb infusion and direct intra-muscular injection 
should allow for a direct extension of the upper end of the dose-escalation of this 
therapy through at least another 20-30-fold, which would be predicted to give a 
result very close to the therapeutic target.  In any case, these preclinical data will 
form the basis for the proposal to the FDA to extend the current IND through the 
next trial. 
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CHAPTER VII 
rAAV Vector Stability in Clinical Conditions 
 
Introduction  
Transition to clinical trial – vector stability 
The remarkable success of rAAV vectors in recent clinical studies of conditions 
such Leber congenital amaurosis 127-131 and hemophilia 132,133 has resulted in a 
dramatic increase in the interest in clinical translation of rAAV-based gene 
therapy.  This will most likely lead to an increasing number of FDA Investigational 
New Drug (FDA-IND) applications for investigational human use of rAAV. Upon 
submission of an FDA-IND, the sponsor must provide data with the Chemistry, 
Manufacturing and Control (CMC) section of the IND to demonstrate the stability 
of the vector under the conditions of storage and its compatibility with containers, 
tubes and delivery devices to be used in the production, storage, transport and 
clinical administration of the vector. See Figure 7.1 for a typical IND workflow.  
These data are also used to provide instructions for clinical investigators in the 
Investigator’s Brochure about appropriate handling of the vector.  Furthermore, 
the Investigator’s Brochure forms the template for important sections of the 
product Package Insert (or “label”) ultimately used to guide clinicians in the 
approved use and administration of the biological agent.  Since very limited 
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stability and compatibility data are currently available in the literature, each IND 
sponsor may need to generate much of the needed data de novo for each IND.   
In the current study, we sought to more systematically investigate the effects on 
rAAV of varying temperatures (including stable temperature storage and freeze-
thaw cycles), diluents (including serum and solutes with varying pH), container 
constituents (plastics, glass and steel) and other environmental exposures.  We 
utilized in vivo biological efficacy of the vector for production of a readily 
measurable transgene product (alpha-1 antitrypsin, AAT) that appears in the 
serum of mice after IM injection of the vector.  These data provide strong 
evidence of the preservation of functional vector under a wide range of such 
conditions.  
Methods 
Vector  
The recombinant AAV1 vectors encoding the chimpanzee alpha-1 anti-trypsin 
gene (ChimpAAT) with a c-myc tag used for this study were packaged, purified, 
and titered by the University of Massachusetts Medical School Vector Core by a 
previously published protocol134. Vector particle concentration was determined 
using silver staining. After production, all vector preparations were stored at -
80oC until use, unless otherwise noted. The chimpAAT gene was under the 
control of a chicken beta-actin promoter with a cytomegalovirus enhancer 
element and had an SV-40 polyadenylation sequence. The total size of the 
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genome (including ITRs) was 3705 base pairs (approximately 79% of the wild-
type AAV genome). 
 
Figure 7.1 Workflow for vector production through to vector delivery. Each point is 
a source of potential loss and may need to be evaluated during preparation of an FDA 
IND. 
 
Mouse Work  
Mice were housed under specific pathogen free conditions and all experiments 
were approved by the University of Massachusetts Institutional Animal Care and 
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Use Committee. Because the reporter transgene used in this study (chimpAAT) 
produces a protein foreign to the murine immune system all studies in this paper 
were done in B6.129S7-Rag1tm1Mom/J (002216, The Jackson Laboratory). These 
mice don’t produce mature B or T cells; stopping the immune response to the 
chimpAAT protein.  Vector was delivered by intra-muscular injection, 1 x 1011 viral 
particles/mouse, in a volume of 50ul to the right hind limb as described 
previously135. The vector was loaded into the syringe just prior to injection. The 
same investigator performed all injections. The dose was determined in a pilot 
where mice were administered the chimpAAT vector at doses from 5 x 1010 viral 
particles/mouse to 1 x 1012 viral particles/mouse. 1 x 1011 viral particles/mouse 
was chosen because it resulted in serum levels of chimpAAT that were easily 
measurable but below the level of saturation. For injection, 14ul of vector was 
mixed with 36ul of either phosphate buffered saline (PBS) or the diluent being 
tested. All groups contain an n of 5 mice. 
AAT ELISA  
An AAT ELISA was performed as previously described88. We determined that the 
humanAAT antibody fully detects the chimpAAT protein by comparing 
humanAAT ELISA results to c-myc ELISA results (data not shown).  
Quantitative Real-Time PCR  
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Vector genomes were determined by TaqMan quantitative PCR as described 
previously 88. Briefly, primers and probes designed to target the SV40 
polyadenylation region of the construct were used. Data was analyzed using 
Eppendorf Mastercycler EP Realplex 2.2 Software (Eppendorf, Hauppauge, NY 
11788), and vector genome (VG) copy number determined using a standard 
curve and normalized to genome copy number per 200ng of genomic DNA. 
 
Statistics  
Each perturbation to the vector was compared to the “Thawed Just Prior” group 
using a two-way ANOVA. Vector copy numbers were analyzed using an unpaired 
t test. P values < 0.05 were considered significant. 
 
Results 
Vector Storage and Temperature Stability  
We compared vector stored at -800C to vector kept for 1 week, 4 weeks, 12 
weeks, and >1 year (never frozen) at 40C (Figure 7.2A). The storage of vector at 
40C for 4 weeks (P = 0.005), 12 weeks (P = 0.0071), and >1 year (P = 0.0153) 
resulted in a statistically significant decrease in chimpAAT serum levels, although 
the absolute serum AAT concentrations were still relatively similar to the vector 
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kept at -800C.  The vector was then exposed to higher temperatures ranging from 
room temperature (200C) for 24 hours to 720C for 20 minutes (Figure 7.2B). The 
only temperatures that resulted in a statistically significant drop in serum 
chimpAAT levels were 550C for 20 minutes (P = 0.0001) and 720C for 20 minutes 
(P < 0.0001) when compared to vector thawed just prior to administration (Figure 
7.2B). However, the serum levels for the 550C for 20 minutes group are still in the 
same range as the control group. When the serum chimpAAT levels were 
analyzed with vector injected after 2-4 freeze/thaw cycles, there was no 
significant difference from the vector thawed just prior (1 freeze thaw cycle) 
(Figure 7.2C). 
Vector Diluent and pH  
When we compared diluents that could be used both for vector administration or 
storage we found that there was a significantly lower serum chimpAAT level with 
Lactated Ringer’s Solution (P = 0.0023) compared to phosphate buffered saline, 
however the serum levels even in that case were still comparable (Figure 7.3A). 
No significant difference was seen with 0.9% saline or Gadolinium (2mM 
concentration) groups (Figure 7.3A). We also investigated the potential effect that 
serum (either complete or C3 depleted) has on gene expression. The complete 
mouse (C57Bl/6J) and human serum were not screened for AAV1 neutralizing 
antibodies. Complement component C3 depleted human serum was obtained 
commercially, and C3 depleted mouse serum was purchased from The Jackson 
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Laboratory (003641 mouse strain). The serum replaced the PBS diluents in these 
experiments. We saw a minor but significant decrease in chimpAAT serum levels 
in the human serum (P < 0.0001) diluted as well and both the mouse (P < 
0.0001) and human (P < 0.0001) C3 depleted serum groups (Figure 7.3B).  
When the expression levels following pH changes to the diluents were 
investigated we found a small but significant drop in chimpAAT expression with 
dilution in a saline solution with a pH of 8.5 (P < 0.0001) but not a pH of 5.5 (P = 
0.5493) (Figure 7.3C). 
Vector Materials Contact  
We looked at chimpAAT expression levels following exposure of the undiluted 
vector to materials that may be encountered during a clinical trial (polypropylene, 
polystyrene, polyethylene, a syringe (polyethylene with rubber stopper), stainless 
steel, and glass) (Figure 7.4). The vector was in contact with each material for 15 
minutes except the syringe where the contact time was increased to 30 minutes. 
There was a small but significant decrease in the serum chimpAAT levels for the 
vector that contacted stainless steel (P = 0.0003), glass (P < 0.0001) and 
polyethylene (P = 0.0001) when compared to the polypropylene (microcentrifuge 
tube) control group (Figure 7.4).  
Vector Extreme Conditions Comparison  
In Figure 7.5A we compared the chimpAAT serum levels between some of the 
harshest conditions discussed in this paper and added a group exposed to UV 
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for 10 minutes. As mentioned prior the 550C for 20 minutes (P = 0.0001) and 
720C for 20 minutes (P < 0.0001) did result in a significant drop in serum 
chimpAAT levels. We saw the most dramatic drop with UV exposure however (P 
< 0.0001). We compared the vector copy number in injected muscle for this 
group of mice, and while there was a decrease in copy number for the perturbed 
groups, particularly the 720C and UV group, the difference did not reach 
statistical significance (Figure 7.5B). When vector particle titers were compared 
before (thawed just prior group) and after perturbation we did see a drop in 
particle concentration in the 550C and 720C groups, a result consistent with 
previously reported work (Figure 7.5C) 136,137. 
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Figure 7.2: Vector Storage and Temperature Stability. Serum AAT ELISA results. A) 
rAAV1 vector storage temperature. Statistically significant decreases in serum AAT 
levels were measure for the 40C for 4 weeks (P = 0.005), 12 weeks (P = 0.0071), and >1 
year (Never Frozen)(P = 0.0153) groups.  B) Temperature stability of rAAV1 vector. 
Statistically significant decreases in serum AAT levels were measure for the 550C for 20 
minutes (P = 0.0001) and 720C for 20 minutes (P < 0.0001). C) Freeze/Thaw cycle 
stability of rAAV1 vector. No significant difference was seen except in Never Frozen 
group. (n = 5) 
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Figure 7.3: Vector Diluent and pH. Serum AAT ELISA results. A) rAAV1 diluent affect.  
Lactated Ringer’s Solution (P = 0.0023) was statistically lower than the phosphate 
buffered saline (PBS) control. B) rAAV1 serum dilution (with or without complement 
component C3. Human serum (P < 0.0001). Mouse (P < 0.0001) and human (P < 
0.0001) C3 depleted serum groups. C) rAAV1 affect of diluent pH. Significant only at pH 
of 8.5 (P < 0.0001). (n = 5) 
 
Figure 7.4: Vector Materials Contact. Serum AAT ELISA results. Significant decrease 
in the serum levels that contacted stainless steel (P = 0.0003), glass (P < 0.0001) and 
polyethylene (P = 0.0001) when compared to the polypropylene (PP) control group. (n = 
5) 
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Figure 7.5: Vector Extreme Conditions Comparison. A) Serum AAT ELISA results. 
550C for 20 minutes (P = 0.0001). 720C for 20 minutes (P < 0.0001). UV 10 minutes (P < 
0.0001). (n = 5) B) Quantitative Real-Time PCR results for vector genome copy number 
in injected muscle. C) Vector particle (VP) titer by silver stain for groups displayed in 
panel A.  
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Summary 
The studies presented here demonstrate the retention of potency of a rAAV1 
vector at temperatures ranging from 4oC to 55oC, at pH ranging from 5.5 to 8.5, 
and after contact with various diluents and container materials. Demonstrable 
loss of vector activity was only observed under two conditions:  heating to 72oC 
and UV exposure for 10 minute all other statistically significant resulted in only a 
relatively small reduction in serum AAT levels. Some residual vector biological 
activity was still noted even under these extreme exposures (approximately 10-
fold and 1000-fold loss, respectively).  The packaged construct used in this study 
is approximately 79% of the size of the wild-type AAV genome. This size 
construct has been shown to have relative thermal stability, with only a modest 
loss of vector particles following exposure to temperatures around 550C, 
something this study reinforced136,137. It was somewhat remarkable that the 
human serum exposure as performed here did not result in neutralization from 
neutralizing antibodies.  AAV1 seropositivity is estimated to be over 70% in the 
general population, but neutralization was not observed under the conditions we 
studied138.  Based on these results, any of the tested diluents and container 
constituents and storage conditions could be employed for future clinical trials. 
 
The stability of both wild-type and recombinant AAV has been commented on in 
a number of previous studies.  Reports describing current Good Manufacturing 
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Practice (cGMP) approaches to rAAV production 139,140 have provided limited, but 
very encouraging, data on stability of stored cGMP rAAV.  Studies indicating 
instability of AAV particles generally have resorted to combinations of factors, 
such as high temperature with extremes of divalent cation concentration 136 or 
high temperature with non-standard vector genome length 137.   
 
Very little data had previously been published with regard to the compatibility of 
rAAV with plastics or other substances that may be found in containers, tubing, 
or delivery devices commonly used to inject therapeutic agents in humans or with 
the diluents in common clinical use.  While the data presented here do not cover 
all possible combinations of materials and diluents, stainless steel is the most 
common constituent for needles in clinical use, polyethylene is commonly used in 
IV tubing and syringes and other plastics and glass may be encountered in 
storage vials.  rAAV was found to be compatible with each of these.  The range 
of pH from 5.5 to 8.5 covers all commonly used clinical IV fluids (0.9% saline, 
unbuffered with lactate, is typically at pH near 5.5).  The data also support 
medium to long-term storage under common refrigeration (4oC) conditions and 
allow for heating such as may occur under a variety of transport conditions from 
a cold storage location to a clinic or operating room. 
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Taken together, the data presented here argue strongly that rAAV is a stable 
biological material under most conditions that are likely to be encountered 
clinically. This could make the preparation of INDs more straightforward and 
facilitate the completion of clinical trials without as much concern about creating 
special storage and handling conditions.  The stability of the agent may well also 
be important in future dissemination of the therapy once it is approved for 
broader clinical use.  This could remove a potential obstacle to widespread 
adoption of the therapy as human gene therapy becomes available to clinicians. 
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CHAPTER VIII 
Discussion 
In this thesis I have outlined the journey from molecular/disease targets through 
animal model development/validation, vector construction, vector testing and 
validation, organ targeting, alternative vector delivery strategies, pharm/tox 
studies, vector stability, clinical trials, and animal studies following clinical trial to 
validate new strategies to overcome clinical trial failures. In this chapter I want to 
review some of the most pertinent points from each chapter as well as outline my 
future research goals. 
 
Cockayne Syndrome Gene Therapy 
CS is a complicated disease with intricate and poorly defined cellular 
mechanisms. While the phenotypes initially described in the mouse models are 
not as easily repeatable as initially hoped, I was still able to define some 
pertinent retinal and metabolic phenotypes that will allow for testing gene therapy 
vectors to provide proof-of-concept that gene therapy can help improve the 
quality of life and potentially life-span of CS patients. A deeper exploration of the 
molecular mechanism of the discovered phenotypes, particularly the metabolic 
phenotype, could provide much needed insight into the clinical disease seen in 
patients.  
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For the future I plan to confirm the metabolic phenotype seen in the CSA and 
CSB mouse models, particularly investigating the marked sensitivity to short-term 
fasting that was noted in both strains. If that phenotype is confirmed then I will 
pursue an AAV gene therapy approach by delivering AAV systemically (encoding 
either the gene for CSA or CSB as appropriate) to the liver in order to determine 
whether this will reverse the sensitivity to fasting and calorie restriction within the 
Cockayne mouse models. This will allow more detailed investigations into the 
affect that gene replacement has on the hepatocyte and particularly the 
mitochondria in these animals.  
In addition to further pursuing the metabolic phenotype in these mice I also plan 
to continue creating a better model of the neurologic phenotype in these mice by 
crossing mice with an XPA mutant background with either CSA or CSB mutant 
mice. As noted above, it has been noted that CSB/XPA mice have a neurologic 
and failure to thrive phenotype but there are no published reports regarding 
CSA/XPA cross mice. I have created these mice and plan to further characterize 
their phenotype and use both the CSB/XPA and CSA/XPA cross mice to 
investigate gene therapy correction of the neurologic phenotype in CS. 
 
Alpha-1 Antitrypsin Deficiency 
This disease has a much more defined genotype/phenotype relationship. The 
road the AATD gene therapy has been a long one as laid out on Chapter III. The 
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goal of defining this journey is to help investigators initiating a gene therapy for a 
new disease target to anticipate some of the steps along the road to a clinically 
applicable gene therapy. In particular the appropriate target organ is critical. As 
laid out in Chapter IV on lung targeting, there are many reasons that this is not 
the ideal organ target for AATD, despite the fact that our current clinical target is 
prevention of the lung disease that results from decreased serum/lung AAT 
levels. Despite the clinical target being prevention of AAT deficiency lung 
disease, as discussed in Chapters III and IV, the optimal target is not the lung or 
the liver because of concerns over both vector delivery/expression as well as 
concerns of precipitating liver disease in patients with the PiZ mutation. Because 
of these concerns along with the fact that target serum levels of AAT were not 
obtained following a large number of intramuscular injection I have pursued a 
limb infusion delivery technique as described and studied in Chapters V and VI 
respectively. Based on the findings of my study in non-human primates we are 
pursuing a hydrodynamic intravenous route of rAAV vector delivery in the next 
human clinical trial. This will allow us to scale up the amount of vector that can be 
delivered without having to increase the number of intramuscular injections. We 
believe based on both the literature as well as my work that this route of delivery 
offers the greatest scalability in terms of dosage with the lowest potential 
morbidity when compared to the intra-arterial dose routes. 
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My final chapter is relevant to clinical trials using rAAV because it demonstrated 
the robust stability that rAAV vectors possess in a variety of situations ranging 
from storage to handling.  
 
Conclusion 
Current translational science requires professionals with experience to help other 
investigators bridge the gap from bench top research to the clinical patients, 
whether they are human or veterinary. Based on the broad translational 
experience I have obtained during my PhD education, as well as my previous 
experience as a veterinarian, I hope to carry my work forward more generally to 
assist others with pre-clinical and clinical trials involving both human and 
veterinary species.  
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APPENDIX I 
Protocol for rAAV Delivery to Murine Lung 
 
Introduction 
This appendix will cover methods of delivering rAAV to the murine lung 
(intranasal, orotracheal intubation and surgical tracheal injection) as well as 
evaluation of gene transfer (serum collection, bronchoalveolar lavage technique, 
and post-mortem collection and processing of lung tissue).  
 
BASIC PROTOCOL 
Intranasal Recombinant Adeno-associated Virus Vector Delivery 
The intranasal route provides a straight-forward method of vector delivery with an 
affordable equipment list and a small learning curve. This leads to easily 
repeatable results in even the novice murine researcher. The downfall of nasal 
delivery is loss of vector in the upper airways (nasal passages, sinuses, and 
pharynx) and gastrointestinal tract rather than having the entire vector dose 
deposited within the lower airways. This may necessitate larger vector doses to 
attain the same level of transduction compared to intra-tracheal delivery. 
Materials 
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Xylazine (20mg/ml) 
Ketamine (100mg/ml) 
Ophthalmic ointment (such as Puralube, Webster Item #: 07-888-2572) 
Webster Veterinary  
www.webstervet.com 
3/10 cc syringe with 31 gauge needle (8mm length needle) (such as: BD Ultra-
Fine II Short Needle Insulin Syringes) 
Or 
100 or 200 microliter micro-pipette tip 
Braintree Scientific: 
http://www.braintreesci.com 
Rodent Intubation Stand (RIS-100) or Rodent Work Stand (RW-A3467) 
Place Velcro on under surface of work stand to allow incisor loop to 
be secured (Figure A1.1A) 
 Incisor loop (210A3490A) 
 
1. Anesthetize using intraperitoneal ketamine and xylazine (see reagents 
and solutions section).  
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The animal must be at a deep enough plane of anesthesia as to prevent 
movement or sneezing/coughing in reaction to the vector administration. 
This can be determined by a negative toe-pinch. Inhalant halothane 
anesthesia also described. Ophthalmic lube can be applied to prevent 
corneal drying. 
2. Position the mouse in dorsal recumbency (on its back) on the rodent work 
stand. 
3. Place incisor loop over the upper incisors and attach the Velcro to the 
corresponding Velcro on the under surface of the rodent work stand (See 
Figure A1.1B).  
A Velcro strip or tape can be used to gently secure the animal to the work 
stand to prevent instability while dosing the animal.  
4. Slowly administer the vector solution via the nostril in a drop-wise fashion. 
Allow the animal to inhale the previous drop prior to administering the next 
drop. A minimum volume of 50ul should be used to ensure maximum 
percent delivery to the lung. For larger volumes it is possible to deliver 
75ul (37.5 per nostril) then allow respirations to return to normal and 
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deliver another 75ul. 
A
CB
 
Figure A1.1: Speculum/Otoscope Assisted Orotracheal Vector Delivery.  A: Set-up 
for speculum assisted intubation: incisor loop, pointed cotton-tipped applicator, stylet 
with catheter, chilled mirror, rodent stand with Velcro to secure incisor loop and chest 
restraint, syringe with vector, syringe to deliver air, otoscope with speculum properly 
positioned (left to right). B. Mouse positioned on rodent work stand with incisor loop and 
chest restraint. Tongue being rolled from mouth using cotton-tipped applicator. Roll 
tongue away from side where speculum will be held. C. Speculum in proper position to 
view larynx (held in dominant hand) and stylet with catheter in place positioned for 
passage into trachea. 
 
5. Gently remove the mouse from the rodent work stand and place in sternal 
recumbency (on chest) in a quiet cage with head and thorax slightly 
elevated (a nestlet or folded paper towel work well for this). 
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This will insure optimal ventilation. 
6. Monitor until recovered from anesthesia then return to home cage. 
 
ALTERNATE PROTOCOL 1 
Speculum/Otoscope Assisted Orotracheal Recombinant Adeno-associated 
Virus Vector Delivery 
Orotracheal intubation provides the ability to directly instill vector into the lung 
without the risks of a surgical procedure or loss of vector in the upper airways. 
This means that the dose of vector reaching the lungs is more tightly controlled 
than with intranasal instillation because essentially the entire amount delivered 
reaches the lung. Orotracheal intubation does have an increased equipment 
investment and a steeper technique learning curve compare to intranasal 
instillation.  
Additional Materials (also see Basic Protocol 1) 
Braintree Scientific: 
Mouse Intubation Pack (RW-A3746) 
Includes: Incisor loop, intubation speculum (to use with otoscope), 
pointed cotton tipped applicators, mirror for verification of 
placement and tutorial video. 
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 Welch Allyn Otoscope (NICAD (RW-A3749) or LI Ion (RW-A3754)) 
 Lung inflation bulbs (LIB-03) 
20 gauge 1.25 inch catheter (BD Angiocath, Becton Dickinson, Sandy Utah) 
2% Lidocaine HCl Jelly (30 ml) (Webster Item #:  07-835-7610) 
1 ml tuberculin slip tip syringe 
1. Anesthetize using intraperitoneal ketamine and xylazine (see reagents 
and solutions section).  
The animal must be at a deep enough plane of anesthesia as to prevent 
movement during the intubation procedure and coughing in reaction to the 
vector administration. This can be determined by a negative toe-pinch. 
Ophthalmic lube can be applied to prevent corneal drying. 
All supplies should be set-up and within easy reach prior to anesthetizing 
the mouse (Figure A1.1A). 
2. Position the mouse in dorsal recumbency (on its back) on the rodent work 
stand 
a. Place incisor loop over the upper incisors and attach the Velcro to 
the corresponding Velcro on the under surface of the rodent work 
stand (See Figure A1.1). 
b. The animal should be positioned so that its back is flat on the work 
stand and the chest is not leaning to either side. The animal should 
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be secured in that position with tape or Velcro over the chest (the 
animal’s front legs will also be under the tape/Velcro) (See Figure 
A1.1B). 
3. Roll the tongue from mouth using pointed cotton-tipped applicator.  
4. Gently insert intubation speculum (attached to otoscope) to the depth of 
the larynx (opening to the trachea) (approximately the depth of the front of 
the ears). The otoscope should be positioned such that the hand holding it 
is located to the side of the mouse’s head and the intubation speculum 
has the concave side facing away from the tongue (See Figure A1.1C). 
5. Gently move the otoscope toward you until the larynx can be visualized. It 
is often necessary to slightly rotate the speculum up to displace the soft 
tissues surrounding the larynx to obtain the best view.  
This will be a very small movement; if the larynx is passed the operator 
will only see the back of the tongue. The speculum will have to be gently 
moved back again and the motion re-attempted.  
6. Once the larynx is visualized, a very small drop of 2% lidocaine jelly can 
be applied using the lidocaine applicator for the intubation pack. The 
speculum is then removed and at least 30 seconds is allowed, for the 
larynx to be desensitized, before intubation is attempted. 
During the 30 second wait, the stylet with catheter should be positioned for 
easy reach during the intubation procedure. 
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7. After 30 seconds repeat steps 3-5 to re-visualize the larynx. 
8. Once the larynx is visualized, the stylet (with catheter attached) should be 
advanced into the tracheal opening. Once the stylet is in place the 
speculum can be removed and the catheter gently advanced down the 
stylet. The catheter should be placed such that the hub (pink portion) of 
the catheter just touches the incisors.  
It is very important not to advance the stylet or catheter past the 
thoracic inlet. No more than 2 attempts to place the stylet/catheter should 
be made in a mouse in one setting or laryngeal swelling and death can 
occur. 
9. Once the catheter is in place the stylet should be removed immediately to 
allow the animal to ventilate normally. 
10. Correct placement of the catheter in the trachea must be determined prior 
to vector administration. 
a. Mirror: Hold the mirror at an angle in front of the tracheal catheter 
opening and observe clouding of the glass as the animal breaths.  
i. Additional confirmation of correct placement can be obtained 
by gently covering the catheter and observing a change in 
breathing pattern that resolves once the finger is removed. 
Only occlude the catheter for 2-3 seconds. 
The mirror must be ice cold to see breath condensate on the glass.  
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b. Lung Inflation Bulb: Attach the inflation bulb gently to the catheter 
and gently squeeze. If the catheter is in the trachea the chest/ribs 
will expand as with a deep breath. If the catheter is in the 
esophagus you may see the abdomen expand. 
If the catheter is in the esophagus you may see some abdominal 
expansion as air is deposited in the stomach when the bulb is 
squeezed. 
11. The vector can then be administered in a 3ul/gram body weight volume 
using a 0.35ml syringe. 
12. Immediately after vector administration instill 0.2ml of air slowly into the 
catheter 2-3 times to ensure that minimal vector remains in the catheter 
and to increase distribution throughout the lung. The air should be instilled 
using a clean 1.0 ml syringe without needle. Care should be taken when 
attaching the syringe to the catheter hub that any vector remaining in the 
hub is not forced out around the syringe. 
13. Immediately following instillation of the air the catheter should be removed 
as any liquid remaining in the catheter will impede normal ventilation. 
14. Gently remove the mouse from the rodent work stand and place in sternal 
recumbency (on chest) in a quiet cage with head and thorax slightly 
elevated (a nestlet or folded paper towel work well for this). 
This will insure optimal ventilation.  
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15. The mouse should be monitored until ambulatory.  
A mild to moderate increase in respiratory effort is expected for the first 
24-36 hours after dosing depending on the volume instilled. 
 
ALTERNATE PROTOCOL 2 
Surgical Tracheal Recombinant Adeno-associated Virus Vector Delivery 
Surgical injection of vector into the trachea has the advantage of improved lung 
vector delivery compared with intranasal instillation and decreased equipment 
costs and ease of learning compared with orotracheal intubation. There is 
increased risk associated with a surgical procedure including hemorrhage, 
incision dehiscence, infection, and longer recovery. Because of the small size of 
the murine trachea there is also a risk of injecting the vector through the trachea 
and targeting the peritracheal tissues or esophagus rather than the lung. 
Materials (also see Basic Protocol 1) 
#15 scalpel blade and handle or 4 ½ inch curved tissue scissors 
(2) Adson tissue forceps (or other delicate tissue forcep) 
4-0 monofilament absorbable suture on a cutting needle (such as PDSII) or 
tissue glue (such as Dermabond) 
Needle holder (for suturing skin) 
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Depilatory cream (such as Nair), scissors, or clippers to remove hair from 
surgical sight 
Chlorhexadine or betadine scrub and 70% alcohol 
IV butterfly catheter with 23 or 25 gauge needle (alternative option) 
 
1. Anesthetize using intraperitoneal ketamine and xylazine (see reagents 
and solutions section).  
The animal must be at a deep enough plane of anesthesia as to prevent 
sensation on incising the skin and injecting the vector. This can be 
determined by a negative toe-pinch. Ophthalmic lube can be applied to 
prevent corneal drying. 
2. Place the animal in dorsal recumbency (on back) and secure chin and 
front limbs with tape. The animal should be on an approximately 45 
degree incline with the head elevated (Figure A1.2A). 
3. Remove the hair from the ventral neck (throat to chest) using depilatory 
cream, scissors or clippers. 
4. Clean the hair and depilatory cream from the area with a damp gauze 
sponge then scrub the skin using chlorhexadine solution followed by 70% 
alcohol. 
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Surgical preparation, including type of surgical scrub used, use of sterile 
surgical drape, sterile surgical gloves, surgical cap, lab coat, and surgical 
mask should be used according to your institution’s animal care and use 
regulations. 
5. Make a 4mm incision centered over the upper portion of the mouse’s neck 
(Figure A1.2B). 
6. Alternatively: Tent the skin in the upper portion of the neck and cut a 4mm 
length of skin with the long direction of the cut extending along the length 
of the neck (not across the neck). 
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Figure A1.2 Surgical Tracheal Delivery. A. Surgical set-up: Forceps (x2), 
scissors, needle holders, scalpel, surgical board on angle, syringe with vector, 
suture, surgical swab wipe, depilatory cream (left to right). B. Vector injection, 
note incision location and tracheal visibility. C. Demonstrating gripping needle 
and placement of suture. D. Properly closed incision. 
 
7. Use the tissue forceps to gently dissect through the subcutaneous tissue 
down to the level of the strap muscles than overlay the trachea.  
8. Make an incision in the strap muscles to expose the trachea.  
9. Once the trachea is visible the needle can be inserted parallel to the 
trachea with the bevel facing up and the point of the needle directed 
toward the lung. (Figure A1.2B). Withdraw needle. 
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Guidelines for volume of vector delivered are the same as for orotracheal 
intubation. The needle should be inserted at an angle pointing toward the 
lung in order to direct the vector toward the lung and not the upper 
airways. When drawing the vector into the syringe prior to administration 
an additional volume of air (0.2ml) should also be draw into the syringe to 
force all vector from the hub of the syringe and the needle into the 
trachea. Alternatively you can use a 23 or 25 gauge butterfly catheter, 
preloading the vector in the tubing and observe the column of fluid move 
with respirations, once the catheter is inserted in the trachea, to ensure 
proper placement. 
10. Close the skin using 2-3 simple interrupted sutures or skin glue. To suture 
the skin the needle should be inserted at a 90 degree angle 1mm from the 
right side of the incision and exit the skin at a 90 angle 1mm from the left 
edge of the incision (Figure A1.2C).  A forcep is used to stabilize the skin 
for needle insertion. A surgical knot is then tied (Figure A1.2D).  
11. Place mouse in sternal recumbency (on chest) in a quiet cage with head 
and thorax slightly elevated (a nestlet or folded paper towel work well for 
this). 
12. The mouse should be monitored until ambulatory.  
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ALTERNATE PROTOCOL 3 
BioLITE Assisted Orotracheal Recombinant Adeno-associated Virus Vector 
Delivery 
This protocol offers an alternative approach to ortracheal intubation to that 
described in Alternate Protocol 1. The equipment costs are less than those for 
speculum aided intubation and the system boasts a smaller learning curve. The 
system consists of a fiber optic illuminator and fiber optic stylet rather than an 
otoscope with speculum and separate stylet used for Alternate Protocol 1. The 
fiber optic stylet allows simultaneous visualization and cannulation of the larynx. 
The intubation catheter used is identical to that used in Alternate Protocol 1. See 
Alternate Protocol 1 for specific pros and cons of orotracheal intubation as a 
delivery route for viral vectors. See Internet Resources section for a video 
demonstrating the BioLITE procedure. 
Additional Materials (also see Alternate Protocol 1) 
Braintree Scientific: 
 BioLITE Mouse Kit (MI-Kit) 
Includes: Fiber optic illuminator, fiber optic stylet, lung inflation 
bulbs, and 5 catheters  
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 Rodent Intubation Stand (RIS-100) or Rodent Work Stand (RW-A3467) 
 
1. Anesthetize using intraperitoneal ketamine and xylazine (see reagents 
and solutions section).  
The animal must be at a deep enough plane of anesthesia as to prevent 
movement during the intubation procedure and coughing in reaction to the 
vector administration. This can be determined by a negative toe-pinch. 
Ophthalmic lube can be applied to prevent corneal drying. 
All supplies should be set-up and within easy reach prior to anesthetizing the 
mouse. 
2. Position the mouse in dorsal recumbency (on its back) on the rodent work 
stand 
a. Place incisor loop over the upper incisors and attach the Velcro to 
the corresponding Velcro on the under surface of the rodent work 
stand (See Figure A1.1). 
b. The animal should be positioned so that its back is flat on the work 
stand and the chest is not leaning to either side. The animal should 
be secured in that position with tape or Velcro over the chest (the 
animal’s front legs will also be under the tape/Velcro) (See Figure 
A1.1). 
3. Roll the tongue from mouth using pointed cotton-tipped applicator.  
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4. Gently insert the BioLite stylet with catheter attached to the level of the 
larynx. Use light to visualized larynx.  
5. Once the larynx is visualized gently pass the stylet into the trachea and 
slowly advance the catheter over the stylet into the trachea. At least 2-3 
mm of the catheter should remain outside the mouse’s mouth once the 
catheter is in position.  
It is very important not to advance the stylet or catheter past the 
thoracic inlet. No more than 2 attempts to place the stylet/catheter should 
be made in a mouse in one setting or laryngeal swelling and death can 
occur. 
6. Once the catheter is in place the stylet should be removed immediately to 
allow the animal to ventilate normally. 
7. The remainder of the protocol is identical to that described in Alternative 
Protocol 1 Steps 10-15. 
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SUPPORT PROTOCOL 1 
Preparing rAAV Vector for Delivery 
The following are the steps we follow to prepare rAAV vectors for delivery to the 
mouse. 
Materials 
Pipette tips (200ul) 
Pipette (20-200ul) 
Parafilm or sterile petri dish 
Ice 
Delivery syringe or pipette (see particular delivery protocol) 
1. Thaw rAAV vector on ice. 
2. Calculate the volume to be delivered based on vector concentration and 
dose desired per mouse. If multiple groups are going to be injected (i.e. 
treatment and control) the same volume of vector should be delivered in 
each mouse, regardless of group. Therefore the most dilute vector will 
determine the volume and maximum dose possible. 
3. If dilution of the vector is necessary it should be done using sterile saline. 
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4. Pipette amount of vector to be dosed per animal. Vector can be pipetted 
onto clean parafilm and drawn up into dosing syringe or pipetted directly 
into dosing syringe if using a syringe with a detachable needle. 
Unlike intravenous preparation all the air does not need to be removed 
from the syringe prior to delivery. 
5. Syringes should then be kept on ice until ready to dose mice. 
6. Any unused, undiluted portion of thawed vector can be kept at 4 degrees 
Celsius. Refreezing rAAV vectors will result in reduction of infective titer.  
 
SUPPORT PROTOCOL 2 
Post-mortem Bronchoalveolar Lavage 
Bronchoalveolar lavage collection allows for quantification of rAAV gene products 
within the distal airways. It is a relatively easy procedure to perform and requires 
minimal equipment. 
Materials 
Additional Materials (also see Alternate Protocol 2) 
Iris scissors 
Sterile Saline 
3 ml syringe 
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1.5 ml eppendorf tube 
 
1. Euthanize mouse according to your institutional animal care guidelines. 
If cervical dislocation is used as part the euthanasia protocol be cautious 
not to damage the trachea. 
2. Follow Alternate Protocol 2 Steps 5-7 to expose the trachea (Figure 
A1.3A). 
3. Using forceps pull a 5-6cm length of suture material underneath the 
trachea (Figure A1.3B). 
4. Make a small cut longitudinally across the trachea using iris scissors (or 
other fine tipped scissors) transecting approximately 1/3 of the tracheal 
diameter. 
Be careful not to completely transect the trachea as this will make 
catheter placement extremely difficult. 
5. Insert the 20 gauge catheter distally (toward the lung) into the trachea to 
the level of the carina (distal most portion of the lung, 2-3mm depending 
on the size of the mouse) and secure in placing using previously placed 
suture (Figure A1.3C). 
6. Instill 500-600 microliters into the lung using a 3ml syringe attached to the 
catheter. 
7. Immediately use the 3ml syringe to draw the fluid back out of the lung. 
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It may be necessary to move the catheter slightly within the trachea to find 
the optimal location for fluid recovery. 
8. Depending on fluid return from first instillation, a second 500 microliters 
can be instilled and collected. 
9. The fluid can then be placed in an eppendorf tube and frozen or spun 
down and the supernatant collected and/or the pellet collected, depending 
on whether a cell-free or cell-rich fraction is desired. 
A B C
D
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Figure A1.3: Post-mortem Tissue Processing. A. Muscles overlying trachea, 
transect with scissors to better access trachea. B. Placement of suture used to 
secure catheter during BAL and close trachea following lung inflation. C. Catheter 
and suture properly placed. D. Small cut in diaphragm just under xyphoid to collapse 
the lungs. E. Careful cut down each side of diaphram from initial opening. F. Chest 
opened and ribs retracted. Needle is pointing to the tip of the left ventricle of heart. 
For flushing blood from lungs make a small cut in left ventricle and insert needle into 
right ventricle (smaller than left). G. Lung inflated with fixative via tracheal catheter.  
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SUPPORT PROTOCOL 3 
Collecting Lung Tissue for Histology and/or Immunohistochemistry or 
Immunofluorescence 
Proper removal of blood from the lungs will decrease autofloresence when 
performing immunofluorescent staining. Fixing the lungs while inflated will aid in 
histologic evaluation of the lung because the alveoli will have a more normal 
architecture rather appearing collapse, allowing identification of individual 
epithelial cells. 
Materials 
Additional Materials (also see Alternate Protocol 2 and Support Protocol 2) 
5 ml syringe 
27 gauge needle 
10 ml conical tube 
Neutral buffered formalin 
 
1. Euthanize mouse according to your institutional animal care guidelines. 
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2. Follow Support Protocol 2 Steps 2-5 to place the tracheal catheter (Figure 
A1.3C). 
3. Open the abdomen using tissue scissors then gently make a small cut in 
the diaphragm in order to collapse the lung (Figure A1.3D-E). 
4. Open the chest cavity by cutting gently along the sternum, careful not to 
cut the heart or lungs (Figure A1.3F). 
5. Flush the blood from the lungs by making a small cut in the left ventricle 
(lower left chamber of the heart (animal’s left)) and flushing 5 ml of sterile 
PBS or saline through the right ventricle (lower right chamber of the heart 
(animal’s right)) using a 5 ml syringe and 27 gauge needle (Figure A1.3F). 
Adequate flushing of the lung will result in white lungs free of blood. Don’t 
insert the needle to deeply into the ventricle or you will puncture into the 
atrium and adequate flushing of the lungs will not be achieved. 
6. If the lungs are to be fixed, inflate the lungs with 1-2 mls of neutral 
buffered formalin using a 3ml syringe attached to the tracheal catheter 
(Figure A1.3G). 
Infuse formalin until lungs are inflated, but not over inflated. Do not 
remove the syringe from the catheter or the formalin will leak out. 
7. Tighten the suture around the catheter to seal the tracheal opening as you 
remove the syringe and catheter together. 
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8. Remove the lungs carefully from the chest cavity by cutting the trachea 
above the suture and carefully lifting the trachea as you cut behind it until 
the lungs are free from the chest cavity.  
Be careful not to cut the lungs while removing or formalin will leak out and 
the lungs will not remain properly inflated. 
9. Place lungs, with suture still closing trachea, into a 10ml conical tube filled 
with formalin. 
The heart can be removed from the lungs before placing in formalin. 
10.  Allow the lungs to fix for 24 hours then replace formalin with sterile 
phosphate buffered saline. 
 
REAGENTS AND SOLUTIONS 
Ketamine/Xylazine Anesthesia 
Xylazine (20mg/ml stock concentration)          0.25 ml   (10 mg/kg dose to mouse) 
Ketamine (100mg/ml stock concentration):     0.5 ml      (100mg/kg dose to 
mouse) 
Sterile Isotonic Saline:                                              5 ml                 
Total Cocktail:                                                           5.75 ml 
 
Dose of cocktail to mouse:  0.10 ml/10 g, intraperitoneally 
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Weigh all animals to determine anesthetic dose. Place the animal in a quiet cage 
following anesthetic administration and allow at least 5 minutes to pass before 
checking anesthetic depth by toe pinch. If adequate anesthetic depth is not 
present allow the animal another 5 minutes in the quiet cage. If still not 
sufficiently anesthetized a 50 mg/kg dose of ketamine alone should be 
administered. If that does not result in sufficient anesthesia then a 0.05 ml/10 g 
dose of the xylazine/ketamine cocktail can be re-administered. 
 
Critical Parameters and Troubleshooting 
Intranasal Recombinant Adeno-associated Virus Vector Delivery 
The main pitfall encountered with intranasal delivery will involve poor distribution 
to the lung. Ensuring that vector is not lost by allowing adequate time for 
inhalation while delivering the vector solution is critical. Poorly anesthetized 
animals are also more likely to swallow the vector rather than inhaling it into the 
lungs (Southam, 2002). Poor lung deposition will also result if the volume 
delivered is less than 50ul total (Southam, 2002). If needle and syringe are used 
to deposit the vector, poor lung delivery could result if the vector is inadvertently 
injected into the nasal epithelium rather than into the nasal passage.  
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Speculum/Otoscope Assisted Orotracheal Recombinant Adeno-associated 
Virus Vector Delivery 
Inadvertent catheter placement into the esophagus is the most common mistake 
that occurs during the orotracheal intubation process. Quickly identifying that the 
catheter is in the wrong location will prevent inadvertent esophageal delivery of 
the vector. In order to avoid catheterizing the esophagus it is imperative to see 
the stylet entering the laryngeal opening. It may be necessary to bend or extend 
the stylet slightly in order to allow better visualization of entry. Repositioning the 
animal so that the head and neck are straight and in-line will also aid in adequate 
visualization of the larynx. Adequate anesthesia will also decrease swallowing 
and provide easier access to the larynx.  
If the catheter is properly positioned within the trachea, not in the esophagus, it is 
normal to notice a change in breathing pattern when delivering the vector and 
subsequent air. 
As mentioned in the protocol, death of the mouse can occur secondary to 
laryngeal trauma if more than 2 intubation attempts are made in one animal. If it 
is critical to dose that animal, it is advisable to allow 24 hours for recovery if any 
reddening or swelling is visualized. 
 
Surgical Tracheal Recombinant Adeno-associated Virus Vector Delivery 
134 
 
 
Potential problems associated with surgical vector delivery include trauma to 
critical structures in the neck including, carotid arteries, jugular veins, and 
esophagus. The carotid arteries and jugular veins are located along side the 
trachea and the esophagus is deep to it. Careful dissection down to the trachea 
should prevent inadvertent damage to any of these structures. Adherence to 
aseptic technique during the surgical procedure should prevent any infections. 
This involves proper hair removal, disinfection of the skin, and sterile surgical 
instruments. Some animal care and use committees may also recommend the 
use of a sterile drape, sterile surgical gloves, surgical mask, and preoperative 
antibiotics to prevent infection. Another common complication in any murine 
surgery is the animals removing the skin sutures. If this occurs it may be 
necessary to reanesthetize the animal and replace the sutures. If several days 
have passed since the surgery enough healing may have occurred such that the 
sutures will not need to be replaced. Some surgeons prefer tissue glue to prevent 
issue of suture removal, however some incision inflammation has been described 
with this product. 
Problems of vector delivery could also occur. Ensuring that the needle is in the 
trachea can be done by drawing back on the syringe prior to and after delivery of 
vector to be sure that air is obtained. The animals should also be adequately 
anesthetized to ensure that the vector is inhaled and not coughed up and 
swallowed. Directing the needle toward the lung and having the animal 
positioned at an angle with the head up should also increase lung deposition. 
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BioLITE Assisted Orotracheal Recombinant Adeno-associated Virus Vector 
Delivery 
See speculum/otoscope section for issues related to adequate visualization of 
the larynx. 
Postmortem Bronchoalveolar Lavage 
Suturing the catheter in place will prevent inadvertent catheter removal during 
delivery and removal of the fluid. Do not insert the catheter too far into the 
tracheal (no more than 2-3mm) or it can push through the distal trachea into the 
mediastinum resulting in no return of fluid.  
Flushing Blood from Lungs 
A poor flush of the lungs can results from inadvertently flushing through the left 
ventricle, pushing the needle too far into the heart, or delivering the PBS solution 
too slowly.  
Inflating Lungs for Fixation 
Poor inflation of the lungs with fixative will occur if the catheter is advanced too 
far and punctures the trachea, if the lungs are cut upon opening of the chest 
cavity, or the trachea is not closed well following catheter removal. Do not insert 
the catheter too far into the tracheal (no more than 2-3mm) to prevent tracheal 
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puncture. Making a small nick in diaphragm before cutting diaphragm or chest 
wall further will allow the lungs to collapse and decrease chance of cutting the 
pulmonary tissue. Wait to inflate the lungs until after the thoracic cavity has been 
opened to prevent lung lacerations. Using blunt tipped scissors to open the 
thorax can also decrease the chance of puncturing the lungs.  
If inflation and formalin fixation is not providing enough tissue fixation, such that 
the lungs still collapse when being sectioned, then 2.5% glutaraldehyde can be 
used in place of formalin for the procedure described above. If the lung tissue is 
going to be frozen in OCT, the lungs can be inflated with OCT instead of 
formalin. 
Anticipated Results 
All of the lung delivery techniques described above should result in widespread 
lung transduction, depending on serotype and promoter used. The duration to 
maximum expression of the delivered transgene will depend on multiple factors, 
including serotype, promoter, and whether vector is single stranded or self-
complementary. Expression should be expected within 7 days with peak 
expression likely between 3-12 weeks.  
Time Considerations 
Intranasal Recombinant Adeno-associated Virus Vector Delivery 
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This procedure can be quickly learned and dosing an animal should take less 
than 1 hour, with 5-10 minutes for anesthesia, 5 minutes or less for dosing, and 
20-30 minutes for anesthesia recovery. Multiple animals can be anesthetized and 
recovered simultaneously, meaning that the largely limiting factor for number of 
animals dosed per hour will be actual vector delivery time. 
Speculum/Otoscope and BioLITE Assisted Orotracheal Recombinant 
Adeno-associated Virus Vector Delivery 
Once this technique is learned dosing a single animal takes approximately 5-10 
minutes for catheter placement and vector instillation. Times for anesthesia and 
recovery are similar to intranasal delivery. This technique can take several 
attempts, meaning multiple animals, before the catheter can be placed in the 
trachea successfully in less than 2 attempts. It is advised to learn the procedure 
on non-experimental animals. 
Surgical Tracheal Recombinant Adeno-associated Virus Vector Delivery 
Anesthesia and recovery times will be similar to intranasal delivery. Surgery and 
delivery time will depend on the operator’s surgical experience. Inexperienced 
investigators may take as long as 20 minutes to complete the technique from 
incision to closure, while experience investigators may be able to complete the 
entire technique in around 5 minutes.  For longer surgical times it may be 
necessary to redoes the anesthetic which will prolong the recovery time. 
138 
 
 
APPENDIX II 
Protocol for rAAV Delivery to Rodent Skeletal and Cardiac Muscle 
 
Introduction 
This appendix will cover methods of delivering rAAV to the rodent skeletal and 
cardiac muscle. Cardiac and skeletal muscles are both transduced well by 
several rAAV serotypes, with AAV9 showing the greatest tropism for both tissue 
types in most animal models 89. In this unit we will discuss several methods to 
deliver rAAV in order to transduce cardiac and/or skeletal muscle. Protocols 
include gene transfer to cardiac and skeletal muscle through intravenous delivery 
of rAAV in adult mice (Basic Protocol 1), gene transfer to skeletal muscle through 
direct intramuscular injection (Alternate Protocol 1) and direct intramuscular 
injection with skin incision (Alternate Protocol 2) in adult mice, gene transfer to 
skeletal muscle through isolated limb infusion in adult mice (Alternate Protocol 3), 
gene transfer to cardiac muscle through intrapericardial injection in neonatal mice 
(Alternate Protocol 4), and gene transfer to the rat myocardium via direct 
injection into the left ventricular wall (Alternate Protocol 5). 
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BASIC PROTOCOL 1 
Gene Transfer to Cardiac and Skeletal Muscle through Intravenous Delivery 
of rAAV in Adult Mice. 
Intravenous delivery allows transduction of both cardiac and skeletal muscles via 
a single injection. Because the vector is delivered systemically the skeletal 
muscle transduction is not limited to one injected muscle group or limb. The 
potential pitfall of intravenous injection is unwanted transgene expression in non-
target organs such as the liver and the central nervous system. Intravenous 
delivery generally requires larger doses of vector when compared to local intra-
muscular or intra-cardiac delivery. Recommended intra-venous vector doses in 
mice range from 1x1012 – 1x1014 vector genomes (vg)/kg, although doses as low 
as 1x1011 vg total have shown detectable luciferase expression in adult mice 
90,96,141. The dose required will depend on the serotype selected, with AAV6-
AAV9 showing significant luciferase expression in the hamstring, gastrocnemius, 
and quadriceps following IV injection 90. In this unit we will discuss the technique 
for intravenous delivery in adult mice.  
Materials 
Mice – choose strain according to planned experiments 
rAAV prepared as described in Support Protocol 1 – diluting the vector to a 
volume of 200ul in sterile PBS 
Sterile phosphate buffered saline (PBS) 
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1ml syringe with 27 gauge 3/8 inch needle 
Mouse restrainer 
Heat lamp or warm water 
Alcohol spray or wipes 
Gauze sponges 
1. Prepare the vector or PBS for injection as described in Support Protocol 1.  
2. Warm the adult mouse for several minutes in its cage under a heat lamp 
or in the mouse restrainer by immersing the tail in warm water to dilate the 
tail vasculature. 
Monitor the mice carefully while under the heat lamp to be sure that 
they don’t over heat. Young adult mice (2-3 months of age) are 
easiest to inject via the tail vein. Older mice (>6 months old) are 
more difficult due to the thicker skin of the tail at that age. 
3. Gently place the mouse in the restrainer. 
The mouse should be restrained tightly enough that movement 
during injection is reduced but not so tightly that breathing is 
impaired. 
4. Spray or wipe the tail with 70% alcohol to better visualize the tail veins 
(Figure A2.1A). 
The tail veins run along the sides of the tail (with the skin 
sometimes visibly raised over the vein), necessitating either rotating 
the tail or laying the restrainer on its side to better visualize them. 
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The tail veins are much more easily visualized in white mice than 
darkly pigmented mice. We recommend that those new to this 
procedure have a second person hold the tail in the rotated position 
while they perform the injection; this also prevents the mouse from 
moving once the needle is positioned properly in the vein (Figure 
A2.1B). For more experienced injectors the injection can be 
performed solo (Figure A2.1D). Note that mice often have a 
pigmented line on the dorsal (top) and ventral (bottom) surface of 
the tail that can be mistaken for the vein.  
5. Grasp the distal end of the tail and insert the needle, bevel side up, about 
½ way down the length of the tail once the vein is visualized (Figure 
A2.1B). The vein lies directly under the skin so the needle should be kept 
parallel to the skin and may need to be redirected to a more shallow 
location once the skin is pierced.  
We recommend injecting ½ way down the tail for several reasons: it 
allows for good visualization of the vein, thinner skin in this region, 
easier manipulation of the needle within the tail, room to move up 
the tail if the injection fails at the first location, and room to visualize 
blanching of the vessel as the vector is injected. Note from Figure 
1B that the tail is held parallel to the floor in the region that is being 
injected. Grasp the syringe such that minimal movement of the 
hand is necessary to check for a flash or blood or inject the vector. 
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This will prevent inadvertent exiting of the vessel during these 
maneuvers.  
6. Once the needle is placed correct location in the vein can be determined 
by gently drawing back on the plunger and observing blood within the hub 
of the needle (Figure A2.1C). 
Note that even when the needle is within the vein, blood is not 
always obtained.  
7. Slowly inject a small amount of vector, if the needle is correctly in the vein 
in vector will flow smoothly and the vein will blanch (turn white) as the 
vector injects. If the area around the vessels turns pale and the plunger 
does not advance easier you are likely not in the vein.  
If the first attempt is not successful try further up on the same side 
or attempt to inject into the other tail vein. If both veins are lost 
during the initial attempts, the animals can be left for 24 hours and 
attempted again.  Monitor the amount of vector that is lost during 
the failed attempt(s). We recommend diluting the amount of vector 
to be injected to a volume of 200ul. This allows for a small amount 
of loss without significantly affecting the titer delivered to the 
mouse. 
8. Once the vector has been injected, slowly remove the needle and place 
pressure on the tail using a gauze sponge until any bleeding has stopped. 
Return the mouse to its cage. 
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Figure A2.1 Intravenous Tail Vein Injection in Adult Mice.  A. Location of the tail veil 
along the side of the tail (arrows). Note that the tail has been rotated so that the side of 
the tail is facing upwards.  B.  Demonstration of the proper positioning of the tail, syringe, 
and injector’s hands to successful tail vein injection.  C. Note blood in syringe seen when 
plunger is drawn back after proper placement of the needle within the vein.  D.  
Demonstration of proper positioning when injecting the tail without a second person to 
hold and rotate the tail. 
 
ALTERNATE PROTOCOL 1 
Gene Transfer to Skeletal Muscle through Direct Intramuscular Injection in 
Adult Mice 
Direct intramuscular (IM) injection is a simple technique that allows delivery of 
vector to a targeted muscle group. Common sites for intramuscular injection in 
the mouse include the tibialis anterior (TA), gastrocnemius, and quadriceps 
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muscle groups. IM injection allows for direct comparisons in transgene 
expression or function between injected and uninjected muscle groups. 
Downfalls of IM injection include variability in transduction due to missing or 
partially missing the target muscle group during the injection. Another limitation is 
the volume of vector that can be injected in each muscle group in the mouse due 
to their small size, this is particularly a problem if small or young mice are being 
injected. Recommended vector dosages for intra-muscular injection range from 
5x108 to 5x1010 vg/site, with the muscle tropism of the serotype selected and the 
concentration of the vector determining the dosage deliverable 96,142,143. Higher 
doses, up to 2.5x1012 have been described, but may be more likely to illicit an 
immune response 92. 
Materials  
Mice – choose strain according to planned experiments 
rAAV prepared as described in Support Protocol 1  
Xylazine (20mg/ml) and Ketamine (100mg/ml) or Isofluorane 
 Contact your institutional animal medicine department for assistance in 
procuring these medications. Injectable grade xylazine and ketamine at the 
concentrations listed should be used. 
Alternatively Isofluorane can be used  
Webster Veterinary  
www.webstervet.com 
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Sterile phosphate buffered saline 
Ophthalmic ointment (such as Puralube, Webster Item #: 07-888-2572) 
Clippers with #40 blade or depilatory cream (such as Nair) 
3/10 cc syringe with 31 gauge needle (8mm length needle) (such as: BD Ultra-
Fine II Short Needle Insulin Syringes) or Hamilton Syringe 
 
1. Prepare the vector to be injected (see Support Protocol 1). For smaller 
muscle groups such as the tibialis anterior or the gastrocnemius a 
maximum of 20-25ul can be injected per muscle. For the quadriceps up to 
50-100ul can be injected 142.  
If a larger vector dose per animal is desired then both hind limbs 
can be injected. 
2. Anesthetize the mouse to be injected with intraperitoneal xylazine plus 
ketamine (see Support Protocol 2 section for instructions on preparing and 
dosing) or 2.5% isofluorane through a nose cone or induction chamber. 
Apply ophthalmic ointment to eyes to prevent corneal drying. 
Xylazine/ketamine will provide a longer period of anesthesia (15-20 
minutes) which may be useful for the more inexperienced operator. 
If induction chamber isofluorane is used the animal will need to be 
left in the chamber for several minutes to allow a long enough 
period of anesthesia for the injection to be carried out. If a nose 
146 
 
 
cone is used, the injection can be performed while the animal is still 
in the cone, preventing waking during injection. 
2. Remove the fur from the area of the limb to be injected, such as the TA or 
gastrocnemius, in order to better visualize the muscle group you are 
targeting (Figure A2.2A). Either clippers or depilatory cream can be used 
to remove the fur. 
As the investigator becomes more experienced with targeting a 
specific muscle group, hair removal will no longer be necessary.  
3. Grasp the mouse such that the limb is held firmly on the limb to be dosed 
at a site above the area to be injected (Figure A2.2B). 
4. Insert needle into the center of muscle group and slowly inject vector. 
If the vector is injected correctly into the tibialis anterior or the 
gastrocnemius the foot will flex upon injection. If no foot flexion is 
noted the muscle may not have been properly injected. It is 
important not to grasp the lower limb during delivery, this will 
prevent foot flexion. 
5. Return the animal to its cage and monitor until fully recovered. Normal 
ambulation (ability to walk) should be monitored the next day.  
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Figure A2.2 Muscle Locations and Positioning for Intramuscular Injections.  A. 
Hind limb of the mouse with fur removed to demonstration location of commonly injected 
muscle groups in the mouse.  B.  Proper positioning, restraint, and needle angle for 
proper injection of the gastrocnemius. The animal positioning and restraint would be 
identical for injecting the TA muscle, only the needle positioning would change. 
 
ALTERNATE PROTOCOL 2 
Gene Transfer to Skeletal Muscle through Direct Intramuscular Injection 
with Skin Incision in Adult Mice 
The background for this method of injection is nearly identical to Alternate 
Protocol 1. Because the muscle is visualized directly the chance of missing the 
target muscle group are minimized. This method is used in cases where certainty 
of the muscle group targeted is absolutely necessary, such a physiology of a 
specific muscle, vector genome isolation from a specific muscle, or retrograde 
targeting/tracking of virus from a specific muscle to the spinal cord.  The common 
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sites for intramuscular injection and vector dosing are identical to those listed for 
Alternate Protocol 1. Incisional complications are possible with this method. 
Materials  
Mice – choose strain according to planned experiments 
rAAV prepared as described in Support Protocol 1  
Xylazine (20mg/ml) and Ketamine (100mg/ml) or Isofluorane 
 Contact your institutional animal medicine department for assistance in 
procuring these medications. Injectable grade xylazine and ketamine at the 
concentrations listed should be used. 
 
Rodent Anesthesia Workstation, including rodent ventilator and isoflurane 
vaporizer (available fully assembled with all necessary accessories)  
Systems Specialties 
1800 Mearns Road, Building 3T 
Warminster, PA 18974 
215-443-9293 
215-443-9640 
(Manufactured by Hallowell EMC, Pittsfield, MA). 
Sterile phosphate buffered saline 
Ophthalmic ointment (such as Puralube, Webster Item #: 07-888-2572) 
Clippers with #40 blade or depilatory cream (such as Nair) 
Chlorhexidine 2% surgical scrub and 70% isopropyl alcohol wipes 
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#11 sterile scalpel blade with handle 
5-0 monofilament suture on a cutting needle (such as polypropylene or nylon) or 
tissue glue (such as Dermabond) 
Needle holder or forceps (if suturing skin) 
3/10 cc syringe with 31 gauge needle (8mm length needle) (such as: BD Ultra-
Fine II Short Needle Insulin Syringes) or Hamilton Syringe 
 
1. Prepare the vector to be injected (see Support Protocol 1) as for Alternate 
Protocol 1.  
2. Anesthetize the mouse to be injected with intraperitoneal xylazine plus 
ketamine or 2.5% isofluorane. Maintain anesthesia using 1.0% isofluorane 
using a nose cone. Apply ophthalmic ointment to eyes to prevent corneal 
drying. 
Xylazine/ketamine may provide an adequate length of anesthesia 
for an operator experienced with murine surgical techniques. 
Animal must remain negative to toe pinch throughout the 
procedure. For more inexperienced operators maintenance 
isofluorane will likely be necessary to maintain anesthesia through 
the entire procedure or a partial dose of xylazine/ketamine can be 
re-administered if the level of anesthesia becomes too light (see 
Reagents and Solutions for dosage). 
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3. Remove the fur from the area of the limb to be injected, such as the TA or 
gastrocnemius, in order to better visualize the muscle group you are 
targeting (Figure A2.2A). Either clippers or depilatory cream can be used 
to remove the fur. 
4. Secure the mouse in lateral recumbency (on its side) with the leg to be 
injected extended and the foot taped in position to maintain extension. 
5. Clean the surgical area with 3 scrubs using a Chlorhexidine 2% surgical 
scrub followed by a scrub with a 70% isopropyl alcohol wipe. 
6. Make a 3-4mm skin incision using a #11 scalpel over the muscle group to 
be targeted. 
Note that the skin on the mouse limb is very thin and great care 
should be taken to incise the skin without damaging the muscle 
underneath.  
7. Insert needle into the center of muscle group and slowly inject vector. 
8. Suture skin using a simple continuous pattern or close using tissue glue.  
Refer to your local animal care and use committee regarding their 
recommendation on using systemic or topical antibiotics with the 
procedure. 
9. Allow mice to recover on a heating pad until it is awake and ambulatory. 
10. Return the animal to its cage and monitor until fully recovered. Normal 
ambulation (ability to walk) should be monitored the next day.  
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ALTERNATE PROTOCOL 3 
Gene Transfer to Skeletal Muscle through Isolated Limb Infusion in Adult 
Mice 
Isolated limb infusion allows vector delivery to the entire muscle mass of the hind 
limb with one injection. This technique was originally described to deliver non-
viral vectors to the limbs of rats but has been subsequently described in mice 
and has been utilized in a mouse model of Pompe disease 144-146.  Dosage 
recommendations for this technique range from 1x109 to 1x1011 vg/animal, 
allowing similar vector doses as IM injection while targeting a larger number of 
muscle groups 146. Disadvantages include difficulty in catheterizing the vessel, 
the need to optimize the volume injected for the animal size being injected, and 
potential complications with the surgical site (infection, incisional dehiscence). 
Materials 
Mice – choose strain according to planned experiments 
rAAV prepared as described in Support Protocol 1  
Xylazine (20mg/ml) and Ketamine (100mg/ml) or Isofluorane 
Contact your institutional animal medicine department for assistance in 
procuring these medications. Injectable grade xylazine and ketamine at the 
concentrations listed should be used. 
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Rodent Anesthesia Workstation, including rodent ventilator and isoflurane 
vaporizer (available fully assembled with all necessary accessories)  
Systems Specialties  
(Manufactured by Hallowell EMC, Pittsfield, MA). 
Polyethylene PE-10 tubing  
30 gauge needles 
High-pressure syringe pump (Harvard Apparatus) 
Heating pad 
Clippers with #40 blade or depilatory cream (such as Nair) 
Ophthalmic ointment 
Chlorhexidine 2% surgical scrub and 70% isopropyl alcohol wipes 
#11 sterile scalpel blade with handle 
5-0 monofilament suture on a cutting needle (such as polypropylene or nylon) or 
tissue glue (such as Dermabond) 
Needle holder or forceps (if suturing skin) 
Small rubber-bands 
 
11. Remove hub from a 30G needles and insert into the end of the PE-10 
tubing. This is the needle that will be used for the injection. Use another 
30G needle and insert the needle into the opposite end of the tubing 
(leaving hub intact for syringe attachment).  
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The length of tubing can be determined based on space between 
the animal and syringe pump. The tubing should be flushed with 
sterile saline or the vector solution prior to insertion of the needle in 
the vein in order to prevent an air embolus when the vector 
injection is initiated. 
12. Prepare vector for injection (see Supplemental Protocol 1). A total volume 
between 200-1000ul can be used with a vector dosing rage of 109 to 1012 
vector genomes.  
13. Anesthetize the mouse to be injected with intra-peritoneal xylazine plus 
ketamine or 2.5% isofluorane through a nose cone or induction chamber. 
Apply ophthalmic ointment to eyes to prevent corneal drying. 
14. Maintain anesthesia during the procedure using 1% isofluorane through a 
nose cone.  
If the procedure is performed quickly intra-peritoneal 
xylazine/ketamine may be sufficient to maintain anesthesia 
throughout the procedure without the need for 1% isofluorane. 
Animal must remain negative to toe pinch throughout the 
procedure. A partial dose of xylazine/ketamine can be re-
administered if the level of anesthesia becomes too light (see 
Reagents and Solutions for dosage). 
15. Position the animal in dorsal recumbency (chest facing upward) with the 
foot of the limb to be dosed securely taped down. Shave or us depilatory 
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cream to remove the hair from the medial (inside) aspect of the limb 
(Figure A2.3A).  
16. Clean the surgical area with 3 scrubs using a Chlorhexidine 2% surgical 
scrub followed by a scrub with a 70% isopropyl alcohol wipe. 
17. Apply a rubber band around the base of the hind limb to occlude blood 
flow (Figure A2.3A). 
18. Make a 0.5-1 cm skin incision using a #11 scalpel along the medial 
saphenous vein (Figure A2.3B). 
Note that the skin on the medial thigh is very thin and great care 
should be taken to incise the skin without damaging the vein or the 
muscle underneath.  
19. Insert needle, bevel side up, until bevel is fully inside of the vein. Start 
distally on the vein (toward the foot) in order to be able to move up slightly 
if the first attempt is unsuccessful.  
An unsuccessful attempt at cannulating the vessel initially could 
cause the vessel to leak when the vector is injected subsequently. 
20. Attach the distal needle hub to the syringe within the syringe pump and 
begin infusion at a rate of 1 mL/minute. 
The vessel should be monitored carefully to ensure that the needle 
remains in the vein and that no significant leakage is occurring 
during injection. It may be necessary to optimize the volume 
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injected for the size mouse being utilized in order decrease vector 
leakage due to high pressure. 
21. After entire dose has been delivered, leave the needle in place for 
approximately an additional minute to allow the pressure to decrease in 
the limb.  
22. Remove the catheter and apply pressure to the vessel until and bleeding 
has stopped. 
23. Suture skin using a simple continuous pattern or close using tissue glue.  
Refer to your local animal care and use committee regarding their 
recommendation on using systemic or topical antibiotics with the 
procedure. 
24. Allow mice to recover on a heating pad until it is awake and ambulatory. 
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Figure A2.3 Location of the Great (Medial) Saphenous Vein for Limb Infusion 
Needle Placement.  A.  Proper restraint of the mouse to locate the great saphenous 
vein as it runs along the inside of the thigh prior to incision.  B.  Proper location of the 
skin incision to expose the great saphenous vein prior to cannulation. 
 
ALTERNATE PROTOCOL 4 
Gene Transfer to Cardiac Muscle through Intrapericardial Injection in 
Neonatal Mice 
This method allows targeting of the neonatal mouse heart with a closed chest 
approach 147,148. With a higher vector dose (2.5X1011 vg) this method allows 
simultaneous transduction of the heart and diaphragm, particularly with AAV8 
and AAV9 89. AAV9 has been shown to have superior cardiac gene transfer in 
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both the rat and mouse heart over a range of doses (2.5X109 - 2.5X1011 vg) 89. 
Because this method targets the heart in neonates it offers a screening tool for 
potential therapeutic transgenes in available mouse models and offers a simple 
alternative to the creation of heart-specific knock-out (using shRNA) or 
transgenic animals 148. 
Materials 
Mice – choose strain according to planned experiments 
rAAV prepared as described in Support Protocol 1  
Hamilton Gastight 250ul glass syringe, series 1725TLL  
Hamilton 33 gauge needle  
25 gauge needle, 1.5 inch length  
Normal saline (sterile) 
Saint Gobain Tygon microbore tubing, Formula S-54-HL (inner diameter: 
0.51mm, wall thickness: 0.51mm, outer diameter: 1.53mm)  
 
1. On day of injection, prepare sufficient vector to allow for a 50uL injection 
per pup and an additional 100uL for losses during preparation and 
injection.   
A vector dosage of 2.5 X 1011 vg/pup (50ul of 5 X 1012 vg/ml) 
results in high level transduction of the heart as well as the 
diaphragm without extensively targeting the liver.  A vector dosage 
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of 2.5 X 1010 vg/pup (50ul of 5 X 1011 vg/ml) results in high level 
transgene expression in the heart with minimal targeting of the 
diaphragm and liver. Keep diluted virus on ice until injection. 
2. Place the Tygon tubing over the 33 gauge Hamilton needle that will be 
used for injection.  The tubing should be cut so that only 3mm of the 
needle is exposed. 
The Tygon tubing will prevent inadvertent advancement of the 
needle beyond the pericardium into the myocardium or left ventricle 
allowing easier maintenance in the pericardial space during vector 
injections. If the needle is advanced too far global cardiac gene 
transfer will not be obtained. 
3. Immediately prior to injection, remove 4-5 day old mouse pups from their 
mother, and place on ice and water mix for approximately 2-3 minutes to 
induce cryoanesthesia.  Mice should not come in direct contact with ice. 
They can either be placed in a latex glove finger and the glove immersed 
in ice up to the neck of the pup or alternatively they can be placed in a 
paper-lined tube which is then packed in ice.  
The pups will become lethargic, but will not cease all activity. Prior 
to 6 days of age mouse pups have a non-fenestrated pericardium, 
limiting vector leakage from the pericardium into the thoracic 
cavity/mediastinum.  
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4. While the pups are being anesthetized on ice, attach the 25 gauge needle 
to the Hamilton syringe and load with the appropriate volume of vector.  
Multiple doses can be drawn up in the syringe at the same time. 
5. Remove the 25 gauge needle used for drawing up the vector, and attach 
the Hamilton 33 gauge needle covered with Tygon tubing (prepared in 
Step 2) to the Hamilton syringe.  Remove any air from the syringe by 
carefully advancing the plunger. 
6. To position the animal for injection, grasp the anesthetized pup by the skin 
at the back of the neck by pinching between the thumb and index finger of 
one’s non-dominant hand.  Rotate one’s wrist so that the pup’s sternum, 
ribs, and xiphoid process (tip of the rib cage that extends over the 
abdomen), can be visualized. 
7. Using one’s dominant hand, insert the Hamilton 33 gauge needle at the 
left costo-xiphoid angle of the pup, and advance the needle superiorly 
3mm (until the Tygon tubing contacts the skin).   
The left costoxiphoid angle is identified as the anatomic location where 
the last rib meets the xiphoid process. This is easy to visualize in mice 
of this age. When advancing the needle it is necessary to maintain and 
angle parallel to the left sternal border (left side of the sternum). This 
will allow the needle to remain within the pericardial sack due the 
pericardium’s attachment to the sternum. This will position the needle 
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below the sternum but above the pericardium while the mouse is held 
in dorsal recumbency (with the sternum facing upward).  
8. Once the needle is in place the vector should be injected slowly in the 
pericardial space. 
 It is imperative to inject the vector slowly.  The operator will 
experience delayed response time due to the small caliber and high 
resistance of the Hamilton 33-gauge needle, and rapid injection will 
result in inadvertent over-injection of vector. Volumes over 50ul are 
associated with increased pup mortality 147. 
9. After injection, return the pup to the mother. It may be necessary to roll the 
pup in the dirty home-cage bedding or wipe the dam’s nose with an 
alcohol wipe to prevent rejection of the pup by the mother. The home cage 
can be placed on a heating pad to improve warming and the pup and 
speed recovery. The pup should not be placed directly on a heating pad or 
under a heating lamp as they may rapidly overheat. 
 
ALTERNATE PROTOCOL 5 
Gene Transfer to the Rat Myocardium via Direct Injection into the Left 
Ventricular Wall 
This method allows delivery of vector to the entire left ventricular free wall of 
adult rats with minimal vector distribution to other organs 89. Use of rat models is 
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important because, as larger animals, rats offer the opportunity to evaluate 
potentially therapeutic genes in a more clinically relevant model.  For example, it 
is technically more feasible to create models of ischemic cardiomyopathy via 
coronary artery ligation or models of pressure overload cardiomyopathy via aortic 
banding in the rat than in the mouse, and these rat models are well-established 
in the literature 149,150. The injection method described here has been 
demonstrated to be safe and is not associated with a significant alteration in 
fractional shortening , ejection fraction, or cardiac geometry in AAV8 and AAV9 
injected animals compared to controls 89. The use of AAV9 results in superior 
transduction of the ventricular wall at doses of 5X1010 – 5X1011 vg/rat compared 
to AAV1, AAV7 and AAV8 89. One limitation of this technique of this technique is 
that it requires invasive thoracic surgery to perform. 
 
Materials 
Adult Rats – see Troubleshooting section for information on strain selection 
rAAV prepared as described in Support Protocol 1  
Buprenorphine  
Cefazolin  
Dobutamine (12.5 mg/ml) 
Xylazine (20mg/ml) and Ketamine (100mg/ml) 
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 Contact your institutional animal medicine department for 
assistance in procuring these medications. Injectable grade xylazine and 
ketamine at the concentrations listed should be used. 
Suture: 4-0 Maxon , 4-0 Vicryl, 5-0 Vicryl (taper and cutting needle), 7-0 Prolene  
 
Rat intubation pack containing intubation speculum, endotracheal intubation 
tubes, an endotracheal tube guide wire, an incisor loop and a brief video tutorial 
on how to perform the intubations (catalog number RW-A37 46) 
Braintree Scientific: 
 http://www.braintreesci.com 
 
Rodent Work Stand for intubation (catalog number: RW A3467, Braintree 
Scientific) 
Otoscope for intubation – rechargeable, Braintree Scientific.  
 
18 gauge angiocath (1.88 inch length) (BD Angiocath Autoguard) 
 
Rodent Anesthesia Workstation, including rodent ventilator and isoflurane 
vaporizer (available fully assembled with all necessary accessories)  
Systems Specialties 
(Manufactured by Hallowell EMC, Pittsfield, MA). 
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Recovery ventilator (optional): Model 141  
NEMI Scientific, Inc.  
http://www.nemiscientific.com/ 
 
Standard surgical instrument pack, sterile drapes, sterile gowns, sterile gloves. 
Chlorhexidine 2% surgical scrub and alcohol wipes 
0.5cc insulin syringe (U-100) with 28 gauge needle, 0.5 inch length   
10ml syringe 
 
1. Anesthetize the rat as described in Support Protocol 3. Administer 
buprenorphine (0.05 mg/kg) and cefazolin (20mg/kg) by subcutaneous 
injection prior to surgery.  Apply ophthalmic ointment to eyes to prevent 
corneal drying. 
2. After induction, place the rat in dorsal recumbency (on its back) on the 
rodent work stand using incisor loop and adjustable restraints. 
3. Use forceps to extend tongue as necessary and visualize the vocal cords 
using the otoscope with speculum attached. Pass the guide wire through 
the vocal cords, and then remove the otoscope while keeping the guide 
wire in place.  Pass the endotracheal tube over the guide wire and into 
position in the trachea; then remove the guide wire. 
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4. Use a 10ml syringe to confirm proper placement in the trachea by 
observing inflation of the chest. Pass a suture around the tube and through 
the cheek to secure the endotracheal tube in position.  
5. Place the rat at the anesthesia work station in right lateral recumbency (left 
side facing up), and connect the endotracheal tube. The work station 
should be set with an oxygen flow rate of 2 liters/minute, a ventilation rate 
of 70 breaths/minute and the isoflurane at 1%.  
Attaching the endotracheal tube to the ventilator may require an 
adaptor which can be acquired from the supplier of the Anesthesia 
Work Station. 
6. Shave the left chest wall and scrub the site three times with chlorhexidine 
solution followed by an alcohol wipe. Drape the chest with a sterile drape. 
7.  Make a 2 cm skin incision over the left fourth intercostal space from dorsal 
to ventral (top to bottom); gently dissect the subcutaneous tissue and 
underlying muscle using sterile forceps.  
8. Enter the thorax through the 4th intercostals space. In order to avoid 
damaging the lung, gently make a small incision in the intercostal tissue 
(tissue between the ribs) and pleura (tissue lining the chest cavity) to allow 
a pneumothorax (air in the chest cavity) to form. This will collapse the lung 
and allow safe expansion of the incision into the thorax.   
9. Once the thorax is entered, visualize the left phrenic nerve (it will appear as 
a thin white line within the pericardium) as it courses over the pericardium, 
165 
 
 
and carefully open the pericardium without disrupting the nerve to expose 
the left ventricle.   
If necessary a small self-retaining rib retractor can be used to 
mazimize heart exposure.  Be careful not to injure the phrenic 
nerve as this will cause paralysis of the hemi-diaprhagm. 
10. Place a 7-0 Prolene suture through the apex (inferior most tip) of the left 
ventricle, and secure the end with a pair of hemostats.   
This suture will allow manipulation of the heart during injection. 
11. Load an insulin syringe with 250 uL of vector.  Grasp the 7-0 suture in 
order to manipulate the position of the heart and increase exposure of the 
left ventricle during injection. 
Care must be taken that the heart is not placed in a position that 
will restrict blood inflow or outflow for more than 30 seconds at a 
time. If cardiac function is compromised 0.1ml of dobutamine can 
be injected into the left ventricular cavity. This can be repeated if 
necessary. 
12. The left ventricular myocardium should be injected in five equally spaced 
aliquots of 50ul.  
Prior to injection of each aliquot, draw back on the needle to ensure 
that you are not in a blood vessel or in the ventricular cavity. If 
blood is drawn back in the syringe the needle should be 
repositioned prior to injection. A blanching of the ventricular wall 
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can be seen with each injection. The needle should be manipulated 
during the injection to maximize the surface area covered by that 
injection. If the entire ventricular surface cannot be covered with 5 
injections the number of injections can be increased, but not the 
total volume (250ul). Increasing the volume beyond 250ul can lead 
to cardiac impairment and death.  
13. After completing the injections, an 18 gauge angiocath should be placed 
through the skin into the thorax via the fifth or sixth intercostal space and 
the needle removed. 
The catheter will allow decompression of the pneumothorax once 
the chest wall is closed in order to restore physiologic negative 
intrathoracic pressure. This will serve as a chest tube to restore 
negative intrathoracic pressure.   
14. Re-approximate the ribs with interrupted 4-0 Maxon suture. Close the 
muscle layer with continuous 4-0 Vicryl suture. The subcutaneous tissue 
should be closed with continuous 5-0 Vicryl suture (taper needle), 
gastrocnemious and the skin with continuous subcuticular 5-0 Vicryl 
suture (cutting needle). 
15. Once suturing is complete, attach a 10cc syringe to the angiocath chest 
tube, and withdraw the plunger of the syringe until resistance is 
encountered. Withdraw the angiocath and syringe from the animal, 
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maintaining resistance until it is completely removed. Give a manual sigh 
breath from the ventilator to re-inflate the lungs completely. 
If multiple procedures are being performed the same day, the rat 
can be moved to a recovery ventilator until spontaneous 
respirations return. 
16. Give buprenorpine and cefazolin at the doses listed above 4 and 12 hours 
post surgery. 
 
SUPPORT PROTOCOL 1 
Preparing rAAV Vector for Delivery  
The following are the steps we follow to prepare rAAV vectors for delivery to the 
mouse. 
Materials 
Recombinant Adeno-associated Virus (rAAV) – rAAV can be produced in-house, 
through a local vector core or via a commercial manufacturer. 
Pipette tips (200ul) 
Pipette (20-200ul) 
Parafilm or sterile petri dish 
Ice 
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Delivery syringe or pipette (see particular delivery protocol) 
1. Thaw rAAV vector on ice. 
2. Calculate the volume to be delivered based on vector concentration and 
dose desired per mouse. If multiple groups are going to be injected (i.e. 
treatment and control) the same volume of vector should be delivered in 
each mouse, regardless of group. Therefore the most dilute vector will 
determine the volume and maximum dose possible. Vector titer 
quantitation should be carried out by the producer of the rAAV virus (either 
a university vector core or commercial manufacturer). If confirmation of 
vector titer is desired in your laboratory, please see Current Protocols in 
Microbiology Chapter 14 reference for specifics on how this can be 
performed. See the dosing protocol that you are using (IM versus IV etc) 
above for appropriate volumes for each route. 
3. If dilution of the vector is necessary it should be done using sterile saline. 
4. Pipette amount of vector to be dosed per animal. Vector can be pipetted 
onto clean parafilm and drawn up into dosing syringe or pipetted directly 
into dosing syringe if using a syringe with a detachable needle. Carefully 
remove all air from syringe without ejecting vector. 
5. Syringes should then be kept on ice until ready to dose mice. 
6. Any unused, undiluted portion of thawed vector can be kept at 4 degrees 
Celsius. Refreezing rAAV vectors will result in reduction of infective titer.  
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SUPPORT PROTOCOL 2: Ketamine/Xylazine Anesthesia Mouse 
Xylazine (20mg/ml stock concentration)          0.25 ml   (10 mg/kg dose to mouse) 
Ketamine (100mg/ml stock concentration):     0.5 ml      (100mg/kg dose to 
mouse) 
Sterile Isotonic Saline:                                              5 ml                 
Total Cocktail:                                                       5.75 mls 
 
Dose of cocktail to mouse:  0.10 ml/10 g, intraperitoneally using a 29 gauge 
needle with a 0.5ml syringe. 
Weigh all animals to determine anesthetic dose. Place the animal in a quiet cage 
following anesthetic administration and allow at least 5 minutes to pass before 
checking anesthetic depth by toe pinch. If adequate anesthetic depth is not 
present allow the animal another 5 minutes in the quiet cage. If still not 
sufficiently anesthetized a 50 mg/kg dose of ketamine alone should be 
administered. If that does not result in sufficient anesthesia then a 0.05 ml/10 g 
dose of the xylazine/ketamine cocktail can be re-administered. 
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SUPPORT PROTOCOL 3 
Ketamine/Xylazine Anesthesia Rat 
Xylazine (20mg/ml stock concentration)          0.75 ml    
Ketamine (100mg/ml stock concentration):     1.8 ml      
Sterile Isotonic Saline:                                          0.45 ml                 
Total Cocktail:                                                        3.0 mls 
 
Initial dosage for a 300 gram rat is 0.15-0.20ml of this cocktail. An additional ½ 
dose can be given if the rat still responds to pain after 5 minutes. 
 
COMMENTARY 
Background Information 
Adeno-associated virus vectors can efficiently transduce both cardiac and 
skeletal muscle through either local or systemic delivery. AAV1, AAV6, AAV7, 
AAV8 and AAV9 each have the ability to efficiently transduce muscle tissue, with 
multiple studies showing that cardiac transduction is most efficiently mediated by 
AAV9 89-91. AAV vectors are capable of targeting both dividing (myoblasts) and 
non-dividing (myofibers and cardiomyocytes) cells with long-term persistence, 
potentially for the life of the animal, possible in non-dividing cells.  
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Targeting cardiac and skeletal muscle tissue in mice and rats allows for 
the development of therapeutic vectors for diseases ranging from muscular 
dystrophies, to Pompe disease, to disorders of fatty acid oxidation that effect 
both the heart and skeletal muscle. Potential cardiac gene therapy targets 
include a wide range of models of cardiomyopathy, both acute and chronic. 
Skeletal muscle, because of its large mass, has also been targeted to express 
non-muscle secreted proteins such as alpha-1 anti-trypsin, coagulation factor IX, 
apolipoprotein E and erythropoietin. It is also possible to transduce both the 
peripheral and central nervous tissue innervating a specific muscle group by 
retrograde transport following intramuscular delivery 92.  
While direct delivery to the heart or specific skeletal muscle groups allows 
for transgene expression in the desired tissue with minimal vector genomes 
reaching other organs, many times systemic delivery of a vector to target multiple 
or all skeletal muscle groups in addition to the heart is desired. In this case 
systemic intravascular delivery may be necessary, but this carries with it the risk 
of expressing the transgene of interest in off-target organs, such as the liver. 
Specificity for muscle and heart following intravenous delivery can be increased 
by including a muscle specific promoter and/or enhancer in the transgene 
cassette 93,94. Another potential option for limiting transgene expression in organs 
other than the muscle would be to include microRNA binding sites in the 
transgene cassette that will mediate the binding of tissue specific microRNAs in 
order to suppress expression of the transgene in those tissues. For example, 
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inclusion of a microRNA binding site for MiR-122 will silence expression in the 
liver 95. 
While all of the procedures described in this unit are scalable to large 
animal species such as dogs, pigs, and non-human primates, vector dosage 
becomes more of an issue because of the large amounts of vector required, 
especially for intravenous dosing. Local delivery such as intra-cardiac and limb 
vascular delivery can reduce the amount of vector required for adequately 
transducing the tissue in these larger species (96-98. It should be noted that the 
vector tropism found even in non-human primates (other than chimpanzees) may 
not correlate to the vector tropism ultimately seen in humans when clinical trials 
are performed. 
 
Critical Parameters and Troubleshooting 
Gene Transfer to Cardiac and Skeletal Muscle through Intravenous Delivery 
of rAAV in Adult Mice. 
It is critical that the operator practice intravenous (IV) injections in multiple mice, 
until successful injection is possible the majority of the time, prior to attempting to 
inject vector. If efficient injections are not obtained consistently variable doses of 
vector will be delivered and the results will be difficult to interpret. The most 
common reason for IV injections to fail are in-adequate vessel dilation prior to 
injection, inaccurate identification of vein (trying to inject into the pigmented line 
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often present on the dorsal and ventral surface of the tail), and movement of the 
needle out of the vein as the plunger is either drawn back or advanced.  
 
Gene Transfer to Skeletal Muscle through Direct Intramuscular Injection in 
Adult Mice 
The most common reason for intramuscular injection failure is missing the target 
muscle group when injecting the vector. Removing the fur from the area over the 
muscle group will aid in targeting the muscle. Observing the foot flex following 
injection of the TA and gastrocnemius will also insure that the muscle was 
injected. It is also imperative that the animal is properly anesthetized when the 
lower limb is being injected to allow the operator time to properly position and 
inject the animal. Anesthesia is not necessary when injecting the quadriceps and 
the back of the thigh (see internet reference for pictures demonstrating injections 
in the caudal thigh). Practicing several mice where a dye (such as methylene 
blue, 1%) is injected and then the muscle dissected will help the new operator 
ensure that they are using proper technique.  
 
Gene Transfer to Skeletal Muscle through Direct Intramuscular Injection 
with Skin Incision in Adult Mice 
This method increases the likelihood of injecting the target muscle group. In 
order for the accuracy of this technique to be optimized the operator must ensure 
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that they know the exact anatomic location of the muscle group to me targeted to 
ensure the incision is properly placed. Careful dissection of the muscles in the 
area on a single mouse prior to attempting the procedure will help ensure that the 
correct muscle is targeted. 
 
Gene Transfer to Skeletal Muscle through Isolated Limb Infusion in Adult 
Mice 
The most difficult aspect of this procedure is cannulation of the vessel with the 
needle. Practicing vessel cannulation on several animals until it can be 
successfully performed is necessary prior to vector dosing. Ensure that the 
syringe pump is set-up and working prior to anesthetizing the mouse to ensure 
that no complications are encountered with the equipment during the procedure. 
Titrating the vector volume delivered, allowing time for the delivered volume to 
disperse in the tissue prior to needle removal, and holding off of the vessel 
following catheter removal will decrease vector dose losses due to vector 
leakage.  
 
Gene Transfer to Cardiac Muscle through Intrapericardial Injection in 
Neonatal Mice 
The Tygon tubing will create a hub at 3mm, which will prevent advancement of 
the needle into the myocardium or left ventricular cavity and allow the 
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investigator to maintain the needle easily in the pericardial space for injection.  It 
is critical for global cardiac gene transfer that the vector be injected into the 
pericardial space and not the myocardium or left ventricular cavity. 
It is critical to inject the vector solution slowly as we have frequently experienced 
a delayed response time when using a Hamilton 33 gauge needle.  This will help 
to avoid over-injection and/or loss of vector.  New investigators may consider 
injecting saline into several control pups to become familiar with the Hamilton 
needle and syringe prior to working with vector. 
The injection volume of 50uL has been optimized previously.  Larger volumes 
have been associated with increased mortality 151.  In our experience, mortality is 
extremely rare with the 50uL injection. 
 
Gene Transfer to the Rat Myocardium via Direct Injection into the Left 
Ventricular Wall 
An instructive video is supplied with the rat intubation pack that first-time users 
may find helpful.  Intubation should proceed as quickly and as smoothly as 
possible.  We have noted that loss of spontaneous respiration can be associated 
with prolonged and/or traumatic intubations.  If this occurs, emergency 
tracheotomy can be performed. 
We have found that the rate of re-intubation can be greatly reduced by extubating 
the rat only after spontaneous movement has been observed. 
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If rats are to be used in an ischemic cardiomyopathy model, we recommend the 
use of Lewis inbred rats.  It has been previously reported that ligation of the left 
anterior descending artery in these rats results in a larger and more uniform 
infarct with lower mortality when compared to Sprague-Dawley rats 152. 
 
Anticipated Results 
All of the cardiac and skeletal muscle delivery techniques described above 
should result in widespread cardiac and/or skeletal muscle transduction, 
depending on serotype and promoter used. The duration to maximum expression 
of the delivered transgene will depend on multiple factors, including serotype, 
promoter, and whether vector is single stranded or self-complementary. 
Expression should be expected within 7 days with peak expression likely 
between 3-12 weeks. Because both cardiac and skeletal muscles have minimal 
cellular turn-over, long-term transgene expression is expected. 
 
Time Considerations 
Gene Transfer to Cardiac and Skeletal Muscle through Intravenous Delivery 
of rAAV in Adult Mice. 
Intravenous delivery is relatively quick once the technique is practiced. It will take 
an average of 5-10 minutes per mouse plus 5 minutes to warm the mouse. 
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Multiple mice can be warmed at once as long as they are monitored to be sure 
they don’t overheat. Efficiency can be increased if once person warms to mice 
and puts in the restrainer and holds the tail while a second person prepares the 
vector for injection and injects the mice. 
 
Gene Transfer to Skeletal Muscle through Direct Intramuscular Injection in 
Adult Mice 
The injection itself takes less than 1 minute, especially once the technique is 
practiced. It takes several minutes for the mouse to become fully anesthetized 
following either intra-peritoneal xylazine/ketamine or isoflurane induction. Time 
per mouse can be decreased if multiple mice are anesthetized at once. It may 
take 30-45 minutes for the mice to fully recover from anesthesia. 
 
Gene Transfer to Skeletal Muscle through Direct Intramuscular Injection 
with Skin Incision in Adult Mice 
This method decreases the likelihood of misinjecting the target muscle group. 
Once the skin incision and closure are mastered the procedure should take less 
than 10 minutes to complete per animal plus time for induction and recovery of 
anesthesia (see direct intramuscular injection section above). 
 
178 
 
 
Gene Transfer to Skeletal Muscle through Isolated Limb Infusion in Adult 
Mice 
It will take least 1 hour per mouse to perform this procedure and an additional 
hour for the mouse to recover from anesthesia. Additional mice can be dosed 
while the first mice are recovering. The most time consuming part for the novice 
operator will be needle placement and skin suturing. 
 
Gene Transfer to Cardiac Muscle through Intrapericardial Injection in 
Neonatal Mice 
This is a very quick procedure.  It will take approximately 3-5 minutes to cool the 
mice in order to induce cryoanesthesia.  Each single injection requires 
approximately 1 minute.  Based on these estimates, a litter of 8-10 mice can 
easily be injected in 15 minutes. 
 
Gene Transfer to the Rat Myocardium via Direct Injection into the Left 
Ventricular Wall 
It will take approximately 20 minutes to sedate and intubate the rat.  The surgical 
injection procedure requires an additional 20 minutes to perform.  Recovery from 
anesthesia can be variable and can take up to 30 minutes per rat.  If multiple 
surgeries are to be performed on the same day, it will be useful to purchase 1-2 
ventilators that will be used solely for recovery.  This will allow the next surgery to 
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start immediately following skin closure of the previous surgery, without the need 
to wait for return of spontaneous respiration.  These ventilators are less 
expensive than the Anesthesia Workstation since they are not equipped with 
isoflurane vaporizes. 
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